CLINICAL STUDY P ROTOCOL 
Title Page 
Protocol Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study 
to Explore the Efficacy and Safety of BIO89-100 in Subject s with 
Severe Hypertriglyceridemia  
Protocol Number:  BIO89 -100-221 
Compound Number: BIO89 -100 
Study Phase:  Phase 2  
Sponsor Name:  89bio, Inc. 
Legal Registered Address:  142 Sansome Street, Second Floor. San Francisco, CA 94104, USA 
Regulatory Agency Identifier Number(s):  IND: 146569 
Sponsor  Representative:   
Approval Date:  03 May 2021 
Version : 3.0 
This clinical study will be conducted in accordance with current Good Clinical Practice (GCP) as 
directed by the provisions of the International Council for Harmonis ation (ICH); United States Code of 
Federal Regulation s (CFR), and European Union Directives and Regulations (as applicable in the 
region of the study); national country legislation; and 89bio’s Stan dard Operating Procedures.  
CONFIDENTIALITY STATEMENT  
This document contains confidential and proprietary information (including confidential commercial information pursuant to 21CFR§20.61) and is a confidential communication of 
89bio, Inc. The recipient agrees that no information contained herein may be published or 
disclosed without the written approval of 89bio, Inc. If there is any actual or suspected breach of this obligation, the recipient agrees to promptly notify 89bio, Inc. 
©2020 89bio, Inc. All rights reserved  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038ANCT #: [STUDY_ID_REMOVED]

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 7 TABLE OF CONTENTS  
SIGNATURE PAGE  ....................................................................................................................... 2  
SPONSOR SIGNATORY:  .............................................................................................................. 2  
PRINCIPAL INVESTIGATOR SIGNATURE PAGE  ................................................................... 3  
PROTOCOL AMENDMENT SUMMARY OF CHANGES  .......................................................... 4  
TABLE OF CONTENTS  ................................................................................................................ 7  
1. PROTOCOL SUMMARY  ......................................................................................... 11 
1.1. Synopsis ...................................................................................................................... 11  
OBJECTIVES AND ENDPOINTS FOR MAIN AND FIBRATE EXPANSION COHORTS  .... 12  
Overall Design  ............................................................................................................................... 14  
NUMBER OF SUBJECTS : ........................................................................................................... 15  
INTERVENTION GROUPS AND DURATION:  ........................................................................ 15  
1.2. Schedule of Assessments (SoA)  ................................................................................. 19  
2. INTRODUCTION  ...................................................................................................... 25 
2.1. Study Rationa le .......................................................................................................... 25  
2.2. Background ................................................................................................................. 26  
2.2.1.  Severe Hypertriglyceridemia  ...................................................................................... 26  
2.2.2.  FGF21  ......................................................................................................................... 27  
2.2.3.  BIO89 -100 .................................................................................................................. 28  
2.3. Benefit/Risk Assessment  ............................................................................................ 29  
2.3.1.  Risk Assessment  ......................................................................................................... 29  
2.3.2.  Benefit Assessment  .................................................................................................... 31  
2.3.3.  Overall Benefit -Risk Assessment  ............................................................................... 31  
3. OBJECTIVES AND ENDPOINTS  ............................................................................ 33 
4. STU DY DESIGN  ....................................................................................................... 36  
4.1. Overall Design  ............................................................................................................ 36  
4.2. Scientific Rationale for Study Design  ........................................................................ 37  
4.3. Justification for Dose  .................................................................................................. 37  
4.4. End of Study Definition .............................................................................................. 38  
5. STUDY POPULATION  ............................................................................................. 39 
5.1. Inclusion Criteria  ........................................................................................................ 39  
5.2. Exclusion Criteria  ....................................................................................................... 40  
5.3. Lifestyle Considerations  ............................................................................................. 43  
5.3.1.  Meals and Dietary Restrictions  .................................................................................. 43  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 8 5.3.2.  Alcohol ....................................................................................................................... 43  
5.3.3.  Activity  ....................................................................................................................... 43  
5.4. Screen Failures  ........................................................................................................... 43  
6. INVESTIGATIONAL PRODUCT  ............................................................................ 44 
6.1. Investigational Product(s) Administered  .................................................................... 44  
6.2. Administration Instructions  ........................................................................................ 44  
6.3. Preparation/Handling/Storage/Accountability  ........................................................... 45  
6.4. Measures to Minimize Bias: Randomization and Blinding  ........................................ 45  
6.5. Emergency Unblinding  ............................................................................................... 46  
6.6. Investigational Product Compliance  ........................................................................... 46  
6.7. Concomitant Therapy ................................................................................................. 46  
6.7.1.  Prohibited Medications/Therapies  .............................................................................. 47  
6.7.2.  Blinded Alerts and Rescue Medications/Therapies .................................................... 47  
6.8. Stopping Rules ............................................................................................................ 48  
6.8.1.  Monitoring and Discontinuation for Suspected Drug- induced Liver Injury (DILI) 
Criteria ........................................................................................................................ 48  
7. INTERRUPTION OR DISCONTINUATION OF INVESTIGATIONAL
PROD
UCT AND SUBJECT DISCONTINUATION/WITHDRAWAL  ................... 50  
7.1. COVID-19- Related Risk Mitigation and Interruption of Investigational Product 
Administration  ............................................................................................................ 50  
7.2. Discontinuation of Investigational Product ................................................................ 51  
7.3. Subject Discontinuation/Withdrawal from the Study  ................................................. 51  
7.4. Lost to Follow-up ....................................................................................................... 52  
8. STUDY ASSESSMENTS AND PROCEDURES  ..................................................... 53 
8.1. Efficacy Assessments  ................................................................................................. 53  
8.2. Safety Assessments  .................................................................................................... 53  
8.2.1.  Physical Examinations  ................................................................................................ 54  
8.2.2.  Vital Signs  .................................................................................................................. 54  
8.2.3.  Electrocardiograms  ..................................................................................................... 54  
8.2.4.  Clinical Safety Laboratory Assessments  .................................................................... 54  
8.3. Adverse Events and Serious Adverse Events ............................................................. 55  
8.3.1.  Time Period and Frequency for Collecting AE and SAE Information ...................... 55  
8.3.2.  Method of Detecting AEs and SAEs .......................................................................... 56  
8.3.3.  Follow-up of AEs and SAEs ...................................................................................... 56  
8.3.4.  Regulatory Reporting Requirements for SAEs .......................................................... 56  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 9 8.3.5.  Pregnancy ................................................................................................................... 56  
8.4. Treatment o f Overdose ............................................................................................... 57  
8.5. Pharmacokinetics  ........................................................................................................ 57  
8.6. Pharmacodynamics and Biomarkers  .......................................................................... 59  
8.6.1.  Pharmacodynamics ..................................................................................................... 59  
8.6.3.  Magnetic Resonance Imaging – Whole Liver Proton Density Fat Fraction  .............. 60  
8.6.4.  Exploratory Analyses  ................................................................................................. 61  
9. STATISTICAL CONSIDERATIONS ....................................................................... 62  
9.1. Statistical Hypotheses  ................................................................................................. 62  
9.2. Sample Size Determination  ........................................................................................ 62  
9.3. Populations for Analyses  ............................................................................................ 63  
9.4. Statistical Analyses  ..................................................................................................... 63  
9.4.1.  General Considerations  .............................................................................................. 63  
9.4.2.  Primary Endpoint(s)  ................................................................................................... 64  
9.4.3.  Secondary Endpoint(s) ............................................................................................... 64  
9.4.4.  Exploratory Endpoints  ................................................................................................ 65  
9.4.5.  Safety Analyses  .......................................................................................................... 65  
9.5. Interim Analyses  ......................................................................................................... 65  
9.6. Data Monitoring Committee  ....................................................................................... 65  
10. SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDE
RATIONS  ................................................................................................. 66  
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight Considerations .................... 66  
10.1.1.  Regulatory and Ethical Considerations  ...................................................................... 66  
10.1.2.  Financial Disclosure  ................................................................................................... 66  
10.1.3.  Informed Consent Process .......................................................................................... 66  
10.1.4.  Data Protection  ........................................................................................................... 67  
10.1.5.  Dissemination of Clinical Study Data  ........................................................................ 67  
10.1.6.  Data Quality Assurance  .............................................................................................. 67  
10.1.7.  Source Documents ...................................................................................................... 68  
10.1.8.  Study and Site Start and Closure ................................................................................ 68  
10.1.9.  Publication Policy  ....................................................................................................... 69  
10.2.  Appendix 2: Clinical Laboratory Tests ...................................................................... 70  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 10 10.3.  Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ....................................................................... 72  
10.3.1.  Definition of AE  ......................................................................................................... 72  
10.3.2.  Definition of Suspected and Unsuspected Adverse Reaction  .................................... 73  
10.3.3.  Definition of Events to Monitor  ................................................................................. 73  
10.3.4.  Definition of SAE  ....................................................................................................... 73  
10.3.5.  Recording and Follow-Up of AE and/or SAE ............................................................ 74  
10.3.6.  Reporting of SAEs ...................................................................................................... 76  
10.4.  Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information ...... 77  
10.5.  Appendix 5: Abbreviations ......................................................................................... 80  
11. REFERENCES ........................................................................................................... 85 
LIST OF TABLES  
Table  1: Intervention Groups Across Main and Fibrate Expansion Cohorts ............................ 16  
Table  2: Schedule of Assessments  ............................................................................................ 19  
Table  3: Discontinuation Criteria in Subjects with Abnormal Baseline ALT or AST Values  . 49 
Table  4: Adverse Event Reporting Periods .............................................................................. 55  
Table  5: Intensive PK Scheme for S ample Collection  ............................................................. 58  
Table  6: Protocol-Required Laboratory Assessments .............................................................. 70  
LIST OF FIGURES  
Figure 1:  Study Schema: Main Cohort ...................................................................................... 18  
Figure 2:  Study Schema: Fibrate Expansion Cohort  .................................................................. 18  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 11 1. PROTOCOL SUMMARY
1.1. Synopsis
Protocol Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the 
Efficacy and Safety of BIO89 -100 in Subject s with Severe Hypertriglyceridemia (SHTG) 
Rationale:  BIO89 -100 is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), a 
meta bolic hormone, regulated by nutritional status, that affects energy expenditure and glucose and 
lipid metabolism. It is secreted mainly by the liver, but also by white adipose tissue, skeletal muscle, 
and the pancreas. The activation of fibroblast growth f actor receptors  (FGFRs)  by FGF21 requires the 
transmembrane protein cofactor β -Klotho, expressed predominantly in metabolic organs, including the 
liver, white adipose tissue, and the pancreas, conferring organ specificity to FGF21 ( Li, et al.  2015; 
Ogawa, et al . 2007). Administration of exogenous FGF21 is being explored as a method to treat 
hypertriglyceridemia  which  is associated with increased risk of acute pancreatitis  (AP) and 
cardiovascular disease (CVD) . Severe hypertriglyceridemia (SHTG), defined as fasting triglyceride 
(TG) levels of greater than or equal to 500 mg/dL, is associated with an increased risk of AP , 
accounting for up to 10% of all AP  episodes ( de Pretis,  2018 ), and an increased risk of non- alcoholic 
fatty liver disease (NAFLD) , non-alcoholic s teatohepatitis (NASH) , and CVD ( Grundy, et al . 201 9). 
Clinical practice guidelines from both the American College of Cardiology/ American Heart 
Association and from the American Association  of Clinical Endocrinologists/American College of 
Endocrinology emphasize the importance of reducing TG in patients with levels above 500 mg/dL. Current treatments for hypertriglyceridemia include fibrates, fish oils, niacin, and statins. While these 
treatments can reduce TG levels, not all patients can reduce TG levels to below 500 mg/dL, signifying 
the need for additional therapies.  
Several non- clinical and clinical studies have shown that administration of various FGF21 analogs had 
beneficial effects on serum lipid and insulin -resistance as well as on liver fat ( Zhang, et al.  2014, 
Gaich , et al.  2013, Sanyal, et al. 2018 ). A pharmacodynamic (PD) effect of BIO89 -100 on TGs has 
been demonstrated, with significant reductions in TG  
 
 
 
In Part 1 of the Phase 1b/2a study BIO89 -100-002, subjects with NASH or NAFLD and high risk for 
NASH (hypertriglyceridemia was not an enrollment criterion ) who received BIO89-100 at 27 mg QW 
for 12 weeks showed a significant beneficial effect on the lipid profile , evaluated as percent change at 
Week 13 (Day 92) (- 28% decrease in TG, - 16% reduction in non- HDL cholesterol and LDL 
cholesterol, p<0.05 for all comparisons) . 
The current data suggest that BIO89 -100 achieves potent and rapid reduc tions in  TG levels  through 
pathways mediated by FGF21, offering novel mechanism s of action. Severe hypertriglyceridemia is 
associated with serious outcomes including risk of significant morbidity and mortality , and BIO89-100 
has the potential for development as an important new therapy . 
This Phase 2 study is designed to assess the efficacy, safety , a
 nd tolerability of different doses and 
dose regimens (QW or every 2 weeks [ Q2W ]), subcutaneous (SC) dosing of BIO89-100 compared to 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 12 placebo in subject s with SHTG . All subjects may be on a background therapy of prescribed fish oils or 
statins but not on niacin, proprotein convertase s ubtilisin/kexin type 9 ( PCSK9 ) inhibitors, or any 
supplements, including non -prescribed fish oils, used to alter lipid metabolism.  Subjects who are not 
taking prescription therapy to lower serum TG may also be enrolled. 
 Subjects in the main  cohort will not be on concurrent fibrate  therapy. In contrast, s ubjects in the 
fibrate expansion cohort will remain on their current stable dose of fibrate therapy.  
The objectives and endpoints are the same for the main cohort and the fibrate expansion cohort. 
Objectives and Endpoint s for Main and Fibrate Expansion Cohorts 
Objectives  Endpoints  
Primary  
•To determine the effect of
BIO89 -100 on serum TG
levels in subject s with
SHTG  (TG ≥500 mg/dL)•Percentage change in serum TG from baseline to W eek 8
Secondary 
•To determine the effect ofBIO89 -100 on selected
serum lipids andlipoproteins•Achieve TG <500 mg/dL at W eek 8
•Percentage change in very low-density lipoproteincholesterol (VLDL -C), low- density lipoprotein
cholesterol (LDL -C), non-high-density lipoprotein
cholesterol (non- HDL -C), high-density lipoprotein
cholesterol (HDL -C), very low-density lipoprotein
triglycerides (VLDL -TG), apolipoprotein B100 (ApoB),
remnant lipoprotein cholesterol (RLP -C) from baseline
to Week  8
•To determine the effect of
BIO89 -100 on high-
sensitivi ty C- reactive
protein (hsCRP)•Percentage change in hsCRP from baseline to W eek 8
•To determine the effect ofBIO89 -100 on metabolic
markers•Percentage change in fasting plasma glucose,adiponectin, and body weight from baseline to W eek 8
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 13 Objectives  Endpoints  
• To characterize BIO89 -100 
pharmacokinetics (PK) • Serum BIO89 -100 concentration  
• PK parameters in Intensive PK subgroup  
o Maximal observed serum concentrations (C max) 
within a dosing interval 
o Area under the serum drug concentration by time 
curve within a dosing interval (AUC 0-tau) 
o Time to achieve C max (tmax) 
o Terminal elimination half- life (t ½) 
Note: Additional PK parameters may be calculated if also deemed appropriate . 
• To characterize BIO89 -100 
PD profile as assessed by MRI -PDFF  • Percentage change and change from baseline in hepatic 
steatosis using MRI -PDFF  
Safety Endpoints  
• To evaluate the safety and tolerability of BIO89 -100 • Frequency of treatment- emergent adverse events 
(TEAEs)  
• Frequency of treatment -emergent serious adverse events 
(TESAEs)  
• Number of subjects who discontinue due to TEAEs 
•  
• To determine the effect of 
BIO89 -100 on liver 
function biomarkers • Change in alanine aminotransferase (ALT) and aspart ate 
aminotransferase (AST) from baseline to W eek 8  
• Other safety assessments  • Incidence and shifts of clinically significant vital signs, 
physical examination findings, electrocardiogram (ECG) 
data, and laboratory abnormalities; safety laboratory evaluations include complete blood count (CBC), blood biochemistry , 24-hour urine cortisol , and urinalysis 
•  
 
 
 
 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 14 Overall D esign  
Study BIO89-100-221 is a randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the 
efficacy, safety, tolerability, PK and PD profiles , and  of BIO89 -100 administered SC 
for 8  weeks. T he main cohort will include ~90 subject s with SHTG  without concurrent fibrate therapy 
and will consist of 5 treatment groups to compare 4  dose levels /regimens  of BIO89 -100 versus 
placebo . The fibrate expansion cohort will include ~36  subjects with SHTG on stable background 
fibrate therap y and with a base line MRI -PDFF ≥  6.0%  and will consist of 2 treatment groups 
comparing one dose regimen of BIO89-100 versus placebo. Investigators whose sites are obtaining 
MRI s should assess if subjects on background fibrate therapy are appropriate for the main cohort 
(acceptable to washout fibrate therapy ) or for the fibrate expansion cohort. For participation in the 
fibrate expansion cohort, investigators should first discuss the potential subject with the Medical 
Monitor. 
The study includes lifestyle stabilization,  TG qualification, treatment, and follow -up periods. 
After signing th e informed consent form and confirmation of general eligibility , subjects will undergo 
further screening assessments to confirm  eligibility over a period of ~6 to  9 weeks. Generally , eligible 
subject s will enter a 4 - or 6 -week l ifestyle s tabilization period ( maximum of 6 week s for subject s 
stopping lipid-altering therapy, minimum of 4 weeks for subject s already on stable, protocol- accepted 
lipid-altering therapy), followed by a ~2-week TG qualification period with qualifying TG 
measurements . If mean TG levels are 
not within the inclusion range, an additional week will be allowed for an addi tional measurement  
  
Individuals who do not meet the criteria for participation in this study (screen failure s other than for 
TGs) may be re -screened , at least 7 days later, if the reason for screen failure is deemed temporary and 
is resolved prior to re -screening (e.g., respiratory infection ). Re -screened subjects will sign a new 
consent and be assigned a new ID. Subjects can only re- screen once.  Re-screen ing subjects who have 
maintained  the lifestyle stabilization  period may be allowed to forgo repeated tests  
at the discretion of the Medical Monitor. Re -screening after C OVID-19 infection requires Medical 
Monitor approval.  Subject s fulfilling all of the qualifying criteria and none of the exclusionary criteria will be randomized 
1:1:1:1:1 for the main cohort  and enter a double-blind, 8-week treatment period during which 
they will be dosed with 1 of 4 doses of BI O89-100 (9 mg QW, 18 mg QW, 27 mg QW, or 36 mg 
Q2W) or placebo.  
Subjects will be enrolled in the fibrate expansion cohort with randomization 1:1  and similarly 
enter a double-blind, 8-week treatment period during which subjects will be dosed with BIO89 -100 
27 mg or placebo QW .  
Randomization in the main cohort will be stratified by T G <750 mg/dL or ≥750 mg/dL (8.47 mmol/L) 
and by whether or not the subject is receiving background therapy (e.g., prescription fish oil and/or 
statins). Randomization in the fibrate expansion cohort will be stratified by TG <750 mg/dL or 
≥750 mg/dL (8.47 mmol/L) only.   
Treatment with investigationa l pr
 oduct (IP) may  be given at home by a home health provider (HHP) or 
at the I nvestigator site, QW, SC into the abdomen. T o maintain the blind,  all subjects will receive 2 SC 
injections at study . Subjects randomized to 36 mg Q2W will receive placebo 
at visits between BIO89 -100 Q2W administrations. Intensive PK is planned to be assessed in a subset 
of subject s (optional participation to include no more than 45 subjects ). Treatment assignment and 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 15 results of the post- baseline lipid panels ( TG,  LDL -C, HDL -C, non-HDL -C, 
VLDL -C, VLDL -TG,  ApoB ,  RPL -C, ), post- baseline MRI -
PDFF, , and PK data will be blinded to subject s, sites, study team and 89bio.  
The efficacy, safety , and tolerability of the treatments will be monitored throughout the study as 
described in the objectives (Section  3).  
Subject s who terminate treat ment early will be requested to have an EOT  
 and an EOS visit 4 weeks later. All subject s who complete the treatme nt 
period will enter a 4 -week follow- up period.  
Disclosure Statement:  This is a parallel treatment study in which subjects, Principal Investigators, 
study site personnel, and 89bio will be blinded to treatment during the double- blind  treatment period.  
Number of Subject s: 
Approximately 90 subjects are planned to be enrolled  in the main  cohort, with 18 subjects in each of 
the BIO89 -100 dose groups (9  mg QW, 18 mg QW, 27 mg QW, or 36 mg Q2W)  and in the placebo 
group. The study aims to enroll ~33% of subjects (~30 subjects total) in the main cohort w ith a 
 
Subjects who terminate early in either cohort may be replaced at  Sponsor’s discretion.  
Intervention Groups  and Duration: 
The main  cohort will consist of 5 treatment groups (details shown in  Table  1), with subjects 
randomized 1:1:1:1:1 to receive  1 of 4 doses of BIO89-100 (9 mg QW, 18 mg QW, 27 mg  QW, or 
36 mg Q2W) or placebo. The fibrate expansion cohort will consist of 2 treatment group s randomized 
1:1 to receive BIO89-100 27 mg or placebo QW . Randomization in the main cohort will be stratified 
by TG <750 mg/dL or ≥750 mg/dL (8.47 mmol/L) and by whether or not they are receiving 
background lipid-modifying therapy , as defined by  prescription fish oil and/or statins . Randomization 
in the fibrate expansion cohort will be stratified by TG <750 mg/dL or ≥750 mg/dL (8.47 mmol/L) only. In both the main and fibrate expansion cohorts, t he total duration of treatment will be 8 weeks , 
follo wed by a 4-week follow-up period. 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 16 Table  1: Intervention Groups  Across Main and Fibrate Expansion Cohorts  
Treatment 
Group  Dose 
Levela Frequency and Route of Administration  Number of 
Subjects  
1 9 mg  QW, SC to abdomen 
 
Main cohort only  18 
2 18 mg  QW, SC to abdomen 
 
Main cohort only  18 
3 27 mg  QW, SC to abdomen 
 
Note:  18 subjects in the main cohort and 18 subjects in the 
fibrate expansion cohort  36 
4 36 mg  Q2W,  
BIO89-100: SC to abdomen 
 
Subjects in the 36 mg treatment group will receive placebo at visits between BIO89 -100 Q2W administrations to maintain 
the blind.  
Placebo: 
 
Main cohort only  18 
5 Placebo  QW, SC to abdomen 
 
Note: 18 subjects in the main cohort and 18 subjects in the fibrate expansion cohort  36 
Abbrevia tions: SC = subcutaneous; QW = weekly; Q2W = e very 2 weeks  
a The actual doses will be ±5% of the mg dose due to technical considerations related to drug withdrawal from the vials 
into the syringes for injection. This difference is considered negligible for subject  exposure.  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 17 The study includes lifestyle stabilization , TG qualification, t reatment , and follow-up periods. 
Screening period: ~6 to 9 weeks 
Lifestyle s tabilization 
period: ~4 weeks (minimum) to ~6 week s (maximum)  
(~6 week s for subjects stopping lipid-altering therapy, ~4 w eeks for 
subject s already on stable, protocol accepted, lipid-altering therapy) 
TG qualification 
period ~2 week s to ~3  week s 
Treatment period  8 week s 
Follow-up period 4 week s 
Data monitoring c ommittee: No data monitoring committee is planned for this study.  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BI O89-100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 18 Figure  1: Study Schem a: Main Cohort 
 
Figure  2: Study Schema: Fibrate Expansion Cohort  
 
Abbreviations: EOT = end of treatment, EOS =end of study, N = number of subjects, QW = once weekly. Q2W = every 2 weeks, TG = triglyceride, V = visit, 
wk = week.  Lifestyle stabilization TG QualificationBIO89 -100 27 mg QW (N=18)
BIO89 -100 18 mg QW (N=18)
BIO89 -100 9 mg QW (N=18)
Placebo QW(N =18)Treatment Period
8 Week
BIO89 -100 36 mg Q2W (N=18)
4 (or 6) weeks 2 (or 3) weeksEOTFollow -up Period
4 WeekRandomization (1:1:1:1:1)
EOS
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BI O89-100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 19 1.2. Schedule of Assessment s (SoA) 
Table  2: Schedule of Assessment s 
Schedule of Assessments 
Study Period ( Duration)  Screening/ 
Lifestyle 
Stabilization 
(Min 
4 weeks to 
Max 
6 weeks)  Screening/ 
TG 
Qualification 
(2 Week)  Screening/ 
TG 
Sample  Double -blind Treatment (8 Weeks)  
Follow -up 
(4 Weeks)  
Visits  
Study Dayb 
Informed consent  x             
Inclusion/ exclusion x x x x          
Randomization    x          
Demography, medical history  x             
Physical examination  x xc xc xc xc xc xc xc xc xc xc x x 
Body weight x x x x    x    x x 
Heightd x             
BMI (derived)  x           x  
Vital signs (BPe, heart ratee, RR) 
and body temperature  x x  x    x    x x 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BI O89-100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 20 Schedule of Assessments 
Study Period ( Duration)  Screening/ 
Lifestyle 
Stabilization 
(Min 
4 weeks to 
Max 
6 weeks)  Screening/ 
TG 
Qualification 
(2 Week)  Screening/ 
TG 
Sample  Double -blind Treatment (8 Weeks)  
Follow -up 
(4 Weeks)  
Visits  
Study Dayb 
Hematology, blood chemistry  and 
coagulation panel  xf  xf xf    xf    xf xf 
Urinalysis  x   x    x    x x 
Thyroid panel ( TSH , free T4, and 
free T3)  x  x         x x 
12-lead ECG  x   x    x    x x 
History of drug and/or alcohol 
abuse , urine drug test,  and 
alcohol consumption test xg  xg,h xh    xh xh  xh xh xh 
Serum lipids, lipoproteins and 
apolipoproteins (TG, , VLDL -
C, VLDL -TG, LDL-C, HDL -C, 
non-HDL -C, RLP -C, , 
ApoB, , )  x xi x    x xi  xi x x 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BI O89-100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 21 Schedule of Assessments 
Study Period ( Duration)  Screening/ 
Lifestyle 
Stabilization 
(Min 
4 weeks to 
Max 
6 weeks)  Screening/ 
TG 
Qualification 
(2 Week)  Screening/ 
TG 
Sample  Double -blind Treatment (8 Weeks)  
Follow -up 
(4 Weeks)  
Visits  
Study Dayb 
Inflammatory biomarker  
(hsCRP)     x    x    x x 
 and s erum adiponectin, total     x    x    x x 
Intensive PK ( optional)k    x x x x x x x x x  
Trough PK (for all subjects)k     x x x  x    x   
HIV, HCV and HBV Serologyl   x            
FSH if required to determine 
menopausal status   x            
Serum pregnancy test (WOCBP)   x           x 
Urine pregnancy test  (WOCBP)   x x    x    x  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BI O89-100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 22 Schedule of Assessments 
Study Period ( Duration)  Screening/ 
Lifestyle 
Stabilization 
(Min 
4 weeks to 
Max 
6 weeks)  Screening/ 
TG 
Qualification 
(2 Week)  Screening/ 
TG 
Sample  Double -blind Treatment (8 Weeks)  
Follow -up 
(4 Weeks)  
Visits  
Study Dayb 
Jug dispensed for 24-hour urine 
collection for cortisol and 
creatininem   x        x   
Archived serum and plasma 
samplesn    x    x    x  
Investigational product dosingp    x x x x x x x x    
AE and SAEs including 
hypersensitivity-related AEsq x x  x    x    x x 
Concomitant medication  x x  x    x    x x 
Review of l ifestyle and a lcohol 
user x x x x    x x  x x x 
MRI-PDFF s    x        x  
FGF21     x          
Shaded columns indicate visits that can be conducted by home health providers . 
Abbreviations:  AE = adverse event ; ; ALT = alanine aminotransferase ; ALP = alkaline phosphatase; ; 
ApoB = apolipoprotein B100 ; ; aPTT = activated partial thromboplastin time; AST = aspartate aminotransferase;  
; BP = blood pressure; BMI = body mass index ; BUN = Blood urea nitrogen; CK = creatine kinase; CKD -EPI = chronic kidney 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BI O89-100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 23 disease epidemiology collaboration; ; DNA  = deoxyribonucleic acid; ECG = electrocardiogram; 
eGFR  = estimated glomeru lar filtration rate; EOS = end of study; EOT = end of treatment; ; FGF21 = fibroblast growth factor 21 ; 
FSH = follicle -stimulating hormone ; GGT  = gamma -glutamyl transferase; HBsAg  = Hepatitis B surface antigen;  HCV  = Hepatitis  C 
Virus; HDL -C = high- density  lipoprotein -cholesterol; HHP = home health provider; HIV = Human Immunodeficiency Virus; hsCRP = high-sensitivity 
C-reactive protein ;  INR = international normalized ratio; LDL-C = low-density  lipoprotein -cholesterol;  
; non-HDL -C = non -high-density  lipoprotein -cholesterol ; MCV = mean corpuscular volume ; MCH = mean corpuscular hemoglobin ; MCHC = mean 
corpuscular hemo globin concentration ; MRI  = Magnetic resonance imaging; MRI -PDFF = Magnetic Resonance Imaging – Whole Liver Proton Density Fat 
Fraction ;  PK = pharmacokinetics; PT = prothrombin time; RNA = ribonucleic aci d; RR = respiratory rate;  
RLP-C = remnant lipoprotein -cholesterol ; SAE = serious adverse event ; SoA = Schedule of Assessments; T3 =  triiodothyronine; T4  = thyroxine ;  
; TG = triglyceride; TSH = thyroid -stimulating  hormone; V = Visit; VLDL -C = very low- density  lipoprotein cholesterol; VLDL -TG = very 
low-density  lipoprotein triglycerides ; WBC = white blood cell; WOCBP = women of childbearing potential . 
Body posture during TG, BP, heart rate, RR and body temperature measurement needs to be the same ( e.g., sitting , semi -erect , or supine) throughout the study 
with resting for at least 5  min prior to measurement at each study visit. 
Fasting blood samples should be taken after  at least  12 hours of fasting . (It is recommended that subjects fast no more than 14 hours .) Fasting includes food and 
all beverages except for non -mineral water.  
Hematology: Hemoglobin, hematocrit, RBC count, reticulocyte count, MCV, MCH, MCHC, platelet count, WBC count, total neutrophils, eosinophils, 
monocytes, basophils, lymphocytes . 
Blood chemistry: BUN, creatinine (eGFR using CKD -EPI equation), fasting plasma glucose, calcium, sodium, potassium, chloride, total CO 2 (bicarbonate), 
AST  (SGOT ), ALT (SGPT), ALP, GGT, total bilirubin,  direct (conjugated) bilirubin, indirect (unconjugated) bilirubin, CK, uric acid, albumin, total protein .  
Coagulation panel: INR, aPTT, PT  
Urinalysis: pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, urobilinogen, urine bilirubin, microscopy 
a = If  is required, only assessment at that visit is TG  measurement . 
b =  
c = Symptom -driven physical assessment for applicable reported AEs . Can be conducted on site during a scheduled or unscheduled visit or by a home health 
provider (HHP) if identified on the delegation log.  
d = Height at screening  only  
e = Starting from randomization, pre -dose BP and pulse will be mea sured in duplicate. The first measurement will be initiated  before dosing with 
sitting/semi- erect or  supine position and resting for at least 5 minutes prior to measurements . BP and pulse are to be repeated  at least  1 minute apart.  Additional 
vital signs measurements may be done if clinically indicated.  
f = Coagulation  pa nel will be done at  only.  
g = History of drug and/or alcohol abuse taken at screening  only. Urine drug test will be performed at  only.  
h= Alcohol breathalyzers will be used . Results >0.01% will be considered as positive.  
i =  
j =  
 
 
  
 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BI O89-100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 24  
iii.  
 
k
 = Subject s will be included in either the Intensive PK scheme ( optional ) or Trough PK scheme ( all subject s). Table  5 details sampling times for the Intensive 
PK scheme .  For the T rough PK scheme, blood samples 
will be taken  
 Note: Where the Intensive PK schedule overlaps with the Trough PK schedule, only 1 PK measurement should be taken at those time points . 
l = Serology tests will include H BsAg , HCV , and HIV 1 and 2 antibodies . HBV and HCV determined by antibodies first and, if positive, by DNA/RNA . 
m = Ambulatory 24-hour urine collection for analysis of cortisol and creatinine to be initiated  the day prior to . Subject will start collection 
24 hours before coming into the clinic and bring the sample to the visit.  The 24 -hour urine collection jug is dispensed at  so collection can be 
completed and brought to , respectively . The jug may be provided at the site or by a n HHP . 
n = Archived for possible analysis of additional . This is optional and by subject consent.   
o =
 
 
p = Subject s randomized to BIO89 -100 36 mg Q2W group will receive BIO89 -100 at  
 
q = When IP is scheduled to be administered by an HHP , a subject’s spontaneous reports of AE/SAE will be reported to the site staff who will follow -up and 
evaluate the need for an unscheduled visit for AE assessment . The sites /HHP  may take non -personally ident ifying photographs of potential injection site 
reactions (optional).   
r = Study coordinators should reinforce maintenance of  eating and exercise habits without weight loss or gain of 5%  for the duration of the study, and alcohol 
consumption restrictions 48  hours prior to fasting blood work .  
s = After a consenting subject’s , the site should preemptively schedule the baseline MRI -PDFF to occur within the following projected visit windo ws to 
ensure an MRI appointment is available  to be performed after the  TG result  ≥350 mg/dL  is known. For the main cohort,  MRI -PDFF is optional  and should 
occur  prior to . For the fibrate  expansion  cohort, MRI -PDFF of ≥ 6.0 % is required for enrollment  and should be performed between   
. The follow -up MRI at   should only be performed if the baseline  liver MRI -PDFF value is ≥ 6.0 %. MRI -PDFF is mandatory in the 
fibrate expansion cohort.  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 25 2. INTRODUCTION  
2.1. Study Rationale  
BIO89 -100 is a glycoPEGylated analog of FGF21, a metabolic hormone, regulated by nutritional 
status, th at affects energy expenditure and glucose and lipid metabolism. It is secreted mainly by 
the liver, but also by white adipose tissue, skeletal muscle, and the pancreas. The activation of 
FGFRs by FGF21 requires the transmembrane protein cofactor β -Klotho, expressed predominantly 
in metabolic organs, including the liver, white adipose tissue, and the pancreas, conferring organ 
specificity to FGF21 ( Li, et al. 2015 ; Ogawa, et al. 2007). Administration of exogenous FGF21 is 
being explored as a method to treat hypertriglyceridemia , which is associated with increased risk 
of AP and CVD. Severe hypertriglyceridemia, defined as fasting TG levels of greater than or equal to 500 mg/dL, is associ ated with an increased risk of AP , accounting for up to 10% of all AP  
episodes ( de Pretis, 2018 ), and an increased risk of NAFLD, N ASH, and CVD ( Grundy, et al. 
2019). Clinical practice guidelines from both th e American College of Cardiology/ American Heart 
Association and from the American Associati on of Clinical Endocrinologists/American College of 
Endocrinology emphasize the importance of reducing TG in patients with levels above 500 mg/dL. Current treatments for hypertriglyceridemia include fibrates, fish oils, niacin, and 
statins. While currently approved therapies are proven to reduce TG levels, the treatment goal of 
alleviating SHTG, i.e., reducing TG levels to below 500 mg/dL remains a significant challenge. In 
the Phase 3 studies with Vascepa® and Epanova®, ~ 50% of subjects did not have TG level 
reductions below  500 mg/dL at the end of the 12- week studies ( Chowdhury, 2012, Chowdhury 
2014).  Patients with TG levels above 500 mg/dL remain at risk for AP  as well as cardiovascular 
and fatty liver diseases. Several non- clinical and clinical studies have shown that administration of 
various FGF21 analogs had beneficial effects on serum lipid and insulin- resistance as well as on 
liver fat (Zhang, et al. 2014, Gaich, et al. 2013, Sanyal, et al. 2018). A PD effect of BIO89 -100 on 
TGs has been demonstrated, with significant reductions in TG levels in a non- human primate 
disease model and in the Phase 1a clinical study , TV47948- SAD-10122.  
 
 
 
 
 
 In Part 1 of the Phase 1b/2a 
study BIO89 -100-002, subjects with NASH or NAFLD and high risk for NASH 
(hypertriglyceridemia was not an enrollment criterion ) who received BIO89-100 at 27 mg QW 
showed a significant benefi cial effect on the lipid profile , evaluated as percent change at Week  13 
(-28% decrease in TG, - 16% reduction in non-HDL cholesterol and LDL cholesterol, p<0.05 for 
all comparisons).  
The current data suggest  that BIO89 -100 achieves potent and rapid reduc tions in TG levels  
through pathways mediated by FGF21, offering novel mechanism s of action. SHTG is associated 
with serious outcomes including risk of significant morbidity and mortality , and BIO89-100 has 
the potential for development as an important new th erapy . 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 26 This Phase 2 study is designed to assess the efficacy, safety , and tolerability of QW or Q2W , SC 
dosing of BIO89-100 compared to placebo in subject s with  SHTG . All subject s may be on a 
background therapy of prescribed fish oils or statins, but not on PCSK9 inhibitors, niacin, or any 
supplements, including non- prescribed fish oils, used to alter lipid metabolism. Subjects who are 
not taking prescription therapy to lower TG may also be enrolled . Subjects in the main  cohort will  
not be on concurrent fibrate  therapy . In contrast, subjects in the fibrate expansion cohort will 
remain on their current stable dose of fibrate therapy.  
2.2. Background 
2.2.1. Severe Hypertriglyceridemia  
Hypertriglyceridemia refers to elevated TG  concentrations in the blood, usually measured after 
fasting but occasionally non- fasting.  High TGs are defined as TG = 200  to 499 mg/dL and very 
high triglycerides, or SHTG  as TG  ≥500 mg/dL ( Berglund, et al. 2012; J elling er, et al. 2017). 
Subjects with elevated leve ls of serum TGs (≥500  mg/dL) are at increased risk of AP , NASH, 
NAFLD and CVD ( Grundy, et al. 201 9). Persistent hypertriglyceridemia is associated with the 
development of AP and CVD. For example, people with high versus low, non- fasting TG 
(580 mg/dL vs 70 mg/dL) were at 5.1 -fold higher risk for myocardial infarction, 3.2-fold higher 
risk of ischemic heart disease, 3.2 -fold higher ri sk for ischemic stroke, and 2.2-fold higher risk for 
all-cause mortality (Nordestgaard , 2016 ). Patients with SHTG are at increased risk of AP with a 
reported 5% and 10% to 20% lifetime risk of AP in patients with TG  >1000 and > 2000 mg/dL 
respectively (Blom,  et al. 2018, Scherer, et al. 2014 ). Kiss et al., reported that elevated TG 
worsens the severity of AP and increases the risk for local and systemic complications, however, 
they reported no specific correlation of AP severity with  extent of hypertriglyceridemia (Kiss,  et 
al. 2018 ). The mechanisms by which SHTG causes pancreatitis are not fully understood but may 
relate to impairment of capillary perfusion in the pancreas, pancreatic cell necrosis and subsequent 
release and activation of pancreatic enzymes ( Blom, et al. 2018). If and when pancreatitis will 
occur in an individual patient is unpredictable. Episodes of acutely -elevated TG levels, associated 
for instance with alcohol use or meals with excessive fat, could increase risk in patients with 
chronically  high TG levels. In most patients who develop AP secondary to SHTG, the condition is 
mild and self -limiting, but ~ 20% of patients suffer severe attacks associated with prolonged 
hospitalization and significant morbidity and mortality . 
Given the high risk of AP  associated with  SHTG , early diagnosis is essential so that treatment can 
be initiated, including simple carbohydrate- and fat- restricted diet, use of medium-chain TG -rich 
foods and alcohol abstinence ( Berglund, et  al. 2012; Jacobson, et al. 2015). 
Current approved therapies for SHTG , as an adjunct to diet,  include multiple fibrates (approved by 
the FDA from 1993 to 2009), niacin (extended release approved by the FDA in 1997), and omega-
3 fatty acids (approved in 2004, 2012, and 2014). Fibrates, niacin, and prescription omega- 3 fatty 
acids, alone or in combination, can reduce TG by 20% to 50% in some patients with moderate to severe hypertriglyceridemia. However, minimal effects are se en in other patients, especially those 
with mutations in genes in the lipoprotein lipase pathway ( Brisson, et  al 2010). Statins have a 
modest TG lowering effect and are used in patients with moderately elevated TG levels, but they should not be used alone in patients with severe or very severe hypertriglyceridemia. 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 27 In patients at high risk for pancreatitis, fibrates remain first line drug treatment, but LDL -C levels 
may increase during therapy with fibrates which is a detrimental effect in this patient population.  
Fibrates are associated with  an increase in the incidence of cholesterol gallstones, increases in 
transaminases and creatinine, among other saf ety and tolerability concerns ( Lopid US Package 
Insert, 2017 ; Tricor US Package Insert, 2018 ). Further, due to increased risk of myopathy, the 
combination of gemfibrozil and statins should be avoided ( Berglund, et  al. 2014).  
The approvals of the omega-3- acids (namely Vascepa® and Epanova ®) represent advances in the 
therapeutic options with improved risk:benefit profiles as compared to the fibrates and niacin 
formulations.  While currently approved therapies are proven to reduce TG levels, the treatment 
goal of alleviating SHTG, i.e., reducing TG levels to below 500 mg/dL remains a significant 
challenge. In  the Phase 3 studies with Vascepa® and Epanova®, ~ 50% of  the subject s did not 
have TG level reduction belo w 500 mg/dL at the end of the 12- week studies ( Chowdhury, 2012; 
Chowdhury, 2014). Patients with TG levels above 500 mg/dL remain at risk for AP  as well as 
cardiovascular and fatty liver diseases. There remains a critical need for new therapies that will 
reliably reduce TG levels below 500 mg/dL rapidly after diagnosis.  
2.2.2. FGF21  
FGF21 is a peptide hormone, which is secreted mainly by the liver. The activation of FGFRs by 
FGF21 requires the transmembrane protein cofactor β -Klotho, expressed predominantly in 
metabolic organs, including the liver, white adipose tissue, and the pancreas, conferring organ specificity to FGF21 ( Li, et al. 2015 ; Ogawa, et al. 2007).  
In patients with hypertriglyceridemia, circulating and/or tissue levels of FGF21 are increased, 
indicating the presence of FGF21 resistance, which can be overcome by administration of 
pharmacological doses of FGF21  (Galman, et al. 2008). On this basis, administration of 
exogenous FGF21 has been explored as a method to treat obesity- associated insulin -resistance 
disorders, in cluding hypertriglyceridemia  (Gaich, et al. 2013 ). 
Native FGF21 has a short life (~2 hours), limiting the potential to use it as a therapeutic agent. Consequently, various methods have been developed to extend the half-life of FGF21, including 
PEGylation. PEGylated FGF21 was shown to provide comparable eff icacy to wild -type FGF21 
despite lower dosing frequency and total cumulative dose, which is likely a result of greatly 
increased in  vivo half-life ( Mu, et al. 2012). In 2 studies in humans, the effects of pegbelfermin 
(BMS -986036; a PEGylated analog of FGF21, which differs from BIO89-100 in PEG size, 
PEGylation site and technology, and location of mutations) were assessed separately in NASH or 
obese subject s. NASH subject s treated for 16 -weeks with pegbelfermin experienced a statistically 
significant reduction in serum TGs versus placebo of 4.8% and 4.7% with doses of 10 mg/d and 20 mg/week, respectively ( Sanyal, et al. 2018). Obese subjects treated for 12 weeks with 
pegbelfermin experienced a ~20% reduction of  serum TGs (p=0.037) at a dose of 20 mg/d ay 
(Charles, et al. 2019). 
Improvements in LDL -C, and HDL-C were also noted in the NASH study primarily with the 
10 mg daily dose. Finally, safety was considered favorable, with no deaths, treatment- related 
serious adverse events ( SAEs ), or discontinuations due to AEs reported. The most frequently 
reported AEs were diarrhea, nausea, and frequent bowel movement ; most of these were mild, and 
none were considered severe in intensity. 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 28 2.2.3. BIO89 -100 
BIO89 -100 is a glycoPEGylated analog of FGF21 that has an N- terminal methionine residue, 
2-point mutations, and a single 20 kDa linear PEG covalently attached via a glycosyl moiety. Both 
point mutations are less likely to be exposed due to steric hindrance by the PEG domain, and 
thereby less likely to trigger an immune response. It has been evaluated in non- clinical 
pharmacology, PK, and toxicology studies and in a recently -completed, first -in-human, single 
ascending dose (SAD) study (TV47948- SAD-10122). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TV47948- SAD-10122, a Phase 1, first- in-human, randomized, double-blind, placebo- controlled 
study to evaluate the safety, tolerability, and PK properties of BIO89-100 following SC 
administration of SAD, has recently been completed. 
 
No significant safety issues have been identified. The most 
common reported AEs (≥2 in the pooled BIO89-100 group) were injection site reactions (all 
common terminology criteria for adverse events [CTCAE ] Grade 1), headache, contact dermatitis , 
and nausea. There were no deaths, SAEs , or discontinuations, and review of ECG, clinical 
laboratories , and vital sign data did not reveal any concerning trends. There was a single CTCAE 
Grade 3 TEAE that was considered not treatment -related (elevated creatine phosphokinase level at 
EOS  in a physical laborer). No other CTCAE Grade 3 or above TEAE was reported. 
Part 1 of BIO89 -100-002 is a randomized, double-blind, placebo- controlled, multiple ascending 
dose (MAD) study to evaluate the safety, tol erability, PK and PD profiles, and  of 
BIO89 -100 administered SC in subjects with NASH or with NAFLD who are at a high risk of 
NASH. Subjects were treated at QW SC doses of 3 mg, 9 mg, 18 mg, and 27 mg, and Q2W SC doses of 18 mg and 36 mg of BIO89 -100 or placebo. D ata from  the MAD study Part 1  
demonstrated favorable safety and tolerability with repeated dosing of BIO89-100 for 12 weeks 
with evidence of clinical efficacy in NASH  (clinically meaningful re ductions in liver fat assessed 
by MRI- PDFF and in ALT).  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 29 A detailed description of the chemistry, pharmacology, efficacy, and safety of BIO89-100 is 
provided in the Investigator’s Brochure (IB).  
2.3. Benefit/Risk Assessment  
 
 
2.3.1.
 Risk Assessment  
  
  
  
 
 
 
  
  
  
  
  
 
 
 
 
 
 
 
 
 
BIO89 -100 is administered subcutaneously; ISRs are well -recognized with SC administration of 
biological agents. As with any biologic drug, exposure to BIO89-100 may potentially provoke an immune response with formation of  that may lead to loss of efficacy, neutralization of 
endogenous FGF21, or adverse effects (e.g., hypersensitivity reaction).  
 
 
 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 30  
 
 
 
 
 
 
 
 
I
ncreased appetite, which has been reported with other FGF21 analogs, occurred in 15.9% of 
BIO89 -100- treated subjects and no placebo -treated subjects in Study BIO89-100-002 (Pa rt 1) 
without a clear dose response. 
In a clinical study of another FGF21 analog, increased blood pressure and heart rate were reported. 
No clinically significant changes in vital signs or ECGs were observed in study 
TV47948- SAD-10122 or study BIO89 -100- 002 (Part 1).  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 31 •  
 
 
 
 
 
 
 
 
 
 
 
 
2.3.2.
 Ben efit Assessment  
Patients with SHTG are at increased risk of AP and cardiovascular comorbidities and require 
significant reductions in TG to lower the risk of AP. As a substa ntial proportion of patients have 
persistent hypertriglyceridemia despite the use of TG lowering medications, there remains a 
critical need for new therapies that will reliably reduce TG levels below 500  mg/dL rapidly after 
diagnosis.  
Long-acting FGF21 ana logs are a promising mode of action for the treatment of SHTG; multiple 
FGF21 analogs have been shown to reduce levels of TG and other lipids in studies of subjects with 
NASH or obesity and Type 2 diabetes mellitus ( Charles ED, 2 019, Gaich G, 2013, Sanyal A, 
2019, Talukdar S, 2016). A PD effect of BIO89 -100 on TGs has also been demonstrated with 
significant reductions in TG levels in the Phase 1 a clinical study, TV47948- SAD-10122, and in a 
non-human primate disease model. Furthermore, BIO89 -100 also offers the potential for broader 
metabolic benefits, including amelioration of fatty liver disease, reduction in LDL -C, increase in 
HDL -C, and improvements in glycemic control that may confer an additional advantage in 
patients with  SHTG , many of whom have metabolic comorbidities. 
Taken together, treatment with BIO89-100 may have a positive impact on serum TG 
concentrations and other metabo lic parameters in treated subjects.   
2.3.3. Overall Benefit -Risk Assessment  
Considering the potential benefits , potential risks , and risk mitigation measures  that have been 
implemented, the benefit- risk profile of administering BIO89 -100 to subject s with SHTG in study 
BIO89 -100-221 is considered to be  favorable. The overall benefit- risk associated with 
administration of BIO89 -100 will be continually re -assessed with the emergence of additional 
data.  
Safety  of trial participants  is of primary  importance. Subject pa rticipation  in the trial during the  
COVID-19 pandemic requires  that site personnel and study subjects follow  key protective  
measures against  COVID-19 infection, aligned with local  requirements  and recommendations.  
89bio and participating  study sites will c ontinually  monitor  the conditions of the pandemic as they  
may affect  the subjects’  safe participation  in the trial. 89bio and  participating  study sites  may  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 32 implement changes to  the protocol based  on an  overall  risk assessment  that includes 
considerations related  to COVID-19 that may result  in changes or alternatives  regarding in -clinic  
visits,  methods of performing assessments,  monitoring, data  collection,  and/or trial participation.  
Provisions concerning IP administration  related  to potential impacts  due to  COVID- 19 are 
described  in Section  7.1.  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 33 3. OBJECTIVES AND ENDPOINTS   
The objectives and endpoints are the same for the main cohort and fibrate expansion cohort. 
Objectives  Endpoints  
Primary   
• To determine the effect of 
BIO89 -100 on serum TG 
levels in subjects with SHTG (TG ≥500 mg/dL )  • Percentage change in serum TG from baseline to Week 8  
Secondary  
• To determine the effect of BIO89 -100 on selected serum 
lipids and lipoproteins  • Achieve TG <500 mg/dL at Week  8 
• Percentage change in VLDL -C, LDL -C, 
non-HDL -C, HDL -C, VLDL -TG, ApoB, RLP- C 
from baseline to Week  8 
• To determine the effect of BIO89 -100 on hsCRP • Percentage change in hsCRP from baseline to Week  8 
• To determine the effect of BIO89 -100 on metabolic 
markers  • Percent change in fasting plasma glucose, adiponectin, and body weight from baseline to Week  8 
• To characterize BIO89 -100 
PK • Serum BIO89 -100 concentration  
• PK parameters in Intensive PK subgroup  
o Cmax within a dosing interval 
o AUC 0-tau within a dosing interval 
o tmax 
o t½ 
• Additional PK parameters may be calculated if 
also deemed appropriate. 
• To characterize BIO89 -100 
PD profile as assessed by 
MRI -PDFF  • Percentage change and change from baseline in 
hepatic steatosis using MRI -PDFF  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 34 Objectives  Endpoints  
Exploratory   
•   
  
  
  
 
  
  
  
 
 
 
  
 
 
  
  
  
  
  
  
 
  
 
  
   
 
 
  
 
 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 35 Objectives  Endpoints  
Safety Endpoints  
• To evaluate the safety and 
tolerability of BIO89 -100 • Frequency of TEAEs  
• Frequency of TESAEs  
• Number of subjects who discontinue due to TEAEs  
•  
• To determine the effect of 
BIO89 -100 on liver function 
biomarkers  • Change in ALT and AST from baseline to Week  8 
• Other safety assessments  • Incidence and shifts of clinically significant vital signs, physical examination findings, ECG data and laboratory abnormalities; safety laboratory evaluations include CBC, blood biochemistry, 24-hour urine cortisol, and urinalysis. 
•  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 36 4. STUDY DESIGN  
4.1. Overall  Design  
Study BIO89-100-221 is a randomized, double-blind, placebo-controlled, Phase 2 study to 
evaluate the efficacy, safety, tolerability, PK and PD profiles , and  of BIO89-100 
administered SC for 8 weeks. The main cohort will include ~90 subject s with SHTG  without 
concurrent fibrate therapy and will consist of 5  treatment groups to compare 4 dose 
levels/regimen s of BIO89 -100 versus placebo ( Figure 1). The fibrate expansion cohort will 
include ~36 subjects with SHTG on stable background fibrate therapy  and with an MRI -PDFF 
≥6.0%  and will consist of 2  treatment groups comparing one dose regimen of BIO89 -100 versus 
placebo ( Figure  2). Investigators whose sites are obtaining MRIs should assess if subjects on 
background fibrate therapy are appropriate for the  main cohort  (acceptable to washout fibrate 
therapy) or for the fibrate expansion cohort. For participation in the fibrate expansion cohort, investigators should first discuss the po tential subject with the Medical Monitor  
The study includes lifestyle stabilization , TG qualific ation, treatment, and follow -up periods. 
After signing the informed consent form and confirmation of general eligibility, subject s will 
undergo further screening assessments to confirm  eligibility over a period of ~6 to 9 weeks. 
Generally , eligible subjects will enter a 4 - or 6- week l ifestyle stabilization period ( maximum of 
6 week s for subject s stopping lipid -altering therapy, minimum of 4 weeks for subj ects already on 
stable, protocol- accepted lipid -altering therapy), followed by a ~2-week TG qualification period 
with qualifying TG measurements  
 
Individuals who do not meet the criteria for participation in this study (screen failure s other than 
for TGs ) may be re -screened, , if the reason for screen failure is deemed 
temporary and is resolved prior to re -screening ( e.g., respiratory infection). Re -screened subject s 
will sign a new consent and be assigned a new ID.  Subjects can only re- screen once.  Re-screening  
subjects who have maintained the lifestyle stabilization  period may be allowed to forgo repeated  
tests  at the discretion of the Medical Monitor. Re -screening after COVID -19 
infection requires Med ical Monitor approval.  
Subject s fulfilling all of the qualifying criteria and none of the exclusionary criteria will be 
randomized 1:1:1:1:1 for the main cohort  and enter a double-blind, 8- week treatment 
period during which they will be dosed w ith 1 of 4 doses of BIO89-100 (9 mg QW, 18 mg QW, 
27 mg QW, or 36 mg Q2W) or placebo.  
Enrollment will begin in the fibrate expansion cohort, with randomization 1:1  to a 
double- blind, 8 -week treatment period during which subjects will be dosed with BIO89 -100 
27 mg or placebo QW .  
Randomization in the main cohort will be stratified by TG <750 mg/dL or ≥ 750 mg/dL 
(8.47 mmol/L) and by whether or not the subject is receiving background therapy (e.g., 
prescription fish oil and/or statins). Randomization in the fibrate expansion cohort will be 
stratified by TG <750 mg/dL or ≥750 mg/dL (8.47 mmol/L) only.  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 37 Treatment with IP will be given at the Investigator site, QW, SC into the abdomen. T o maintain 
the blind, all subje cts will receive 2 SC injections . Subjects 
randomized to 36 mg Q2W will receive placebo at visits between BIO89 -100 Q2W 
admin istrations . Intensive PK is planned  to be assessed for  a subset of subject s (optional 
participation with no more than 45 subject s). Treatment assignment and results of the post -
baseline lipid panels ( TG, , LDL -C, HDL -C, non-HDL -C, VLDL -C, VLDL -TG, , 
ApoB, , RPL- C, ), post- baseline MRI -PDFF, , and PK data will be blinded to 
subjects, sites, study team, and 89bio.  
The efficacy, safety , and tolerability of the treatments will be monitored throughout the study as 
described in the objectives ( Section  3).  
Subjects who terminate treat ment early will be requested to have an EOT visit  
 and an EOS visit 4 weeks later. All subjects who complete the treatme nt 
period will enter a 4 -week follow- up period.  
4.2. Scientific Rationale for Study Design 
BIO89 -100-221 a Phase 2, randomized, double-blind, placebo- controlled  study designed to assess 
the efficacy, safety and tolerability of different doses and dose regimens ( QW or Q2W ) of SC  
BIO89 -100 compared to placebo in subject s with SHTG . The study will separately evaluate the 
response to BIO89-100 in subjects who are not on concurrent fibrate therapy and subjects who 
remain on their current fibrate therapy. The primary  and secondary efficacy  endpoints, safety, and 
PK are characteristic for  this type of study. Results from this study  will provide proof-of-concept 
data to inform dose selection in the future Phase 3 clinical program. 
Fibrate therapy is commonly used to lower TGs in patients with SHTG. Fibrates act by agonizing PPAR⍺, which  stimulates the release of FGF21 in the liver. It is unknown if the levels achieved by 
exogenous FGF21 supplementation with BIO89 -100 will be greater than, or have an add- on effect  
to, those achieved by fibrate -induced PPAR⍺ agonism alone.  
One potential additional benefit of BIO89-100 is reduction in liver fat content. Fatty liver has been shown to be significantly associated with moderately severe or severe acute pancreatitis ( Yoon, et 
al. 2017). In Study BIO89-100-002 (Part 1), BIO89- 100 (27 mg QW) reduced liver fat as assessed 
by MRI- PDFF up to 60%. Fibrates do not reduce liver fat content. To evaluate this additional 
potential benefit, only subjects with liver fat content ≥ 6.0% by MRI -PDFF at baseline will be 
enrolled into the fibrate expansion cohort.  
4.3. Justification for Dose  
Five groups of SHTG subject s are planned to be dosed, SC × 2 per visit, into the abdomen, with 
either placebo or 1 of 4 doses of BIO89-100 (9 mg QW, 18 mg QW, 27 mg QW, or 36 mg Q2W) 
(Figure 1 ). 
These dose regimens were selected based on non- clinical  pharmacolog ical and PK  models mainly 
in spontaneously diabetic monkeys , review of clinical PK , and efficacy data from the single 
ascen ding dose clinical study TV47948- SAD-10122 and PK modeling. 
 
 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 38  
 
 
 
 
 
 
 
 
 
 
Th
e selected dose of 27 mg QW was  chosen  for the fibrate expansion cohor t based on the results 
observed in subjects with NASH or NAFLD and high risk for NASH in Study BIO89 -100-002 
(Part 1), in which 10 subjects were randomized to  that dose.   
 
 
 
  
The benefit/risk assessment for BIO89 -100 at the chosen doses is presented in Section  2.3. Based 
on these data, the dose regimens are anticipated to be safe, and of sufficient duration to reach 
steady state, to maintain PD responses over the dosing intervals, and to cover the dose range 
where key PD responses are predicted to be associated with important clinical outcomes to be 
assessed in subsequent studies.  
4.4. End of Study Definition  
A subject is considered to have completed the study if he/she has completed all phases of the study 
including the last scheduled procedure shown in the Schedule of Assessments (SoA) ( Table  2). 
The EOS is defined as the date of the last visit of the last subject in the study.  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 39 5. STUDY POPULATION  
5.1. Inclusion Cr iteria  
Subject s are eligible to be included in the study only if all of  the following criteria apply:  
1. Subject understands the study design and has been informed of the investigational nature 
of the study. Subject has given voluntary, written, informed cons ent to take part in this 
study. 
2. Subject agrees to be compliant and is capable of completing the required study assessments.  
3. Male or female age ≥21 to ≤75 years at time of signing informed consent . 
4. All subjects (male or female) who are of childbearing poten tial must agree to use 
highly-effective, double contraception ( with male /female partners) during the study. 
Double contraception is defined as use of a condom by the male partner, combined with use of 1 of the following forms of highly- effective contraception by the female partner:  
a. Oral contraceptive pills  
b. Depot or injectable contraceptive  
c. Intrauterine device (IUD) 
d. Contraceptive patch ( e.g., Xulane®) or NuvaRing® 
e. Documented evidence of tubal ligation  at least 6  months prior to the screening visit).  
Male subjects with a history of vasectomy should also use condoms as double 
contraception during the study.  Use of highly-effective, double contraception must 
continue for 30 days or 5 half- lives (whichever is longer) after the last dose of IP . Female 
subjects must  not donate oocytes during this time. Male subjects must not donate sperm 
during this time. Rhythm methods are not considered as highly- effective methods of birth 
control. Subject abstinence for the duration of the study and 30 days or 5 half- lives 
(whichever is longer) after last dose of IP  is acceptable if it is the subject’s regular practice.  
5. Females of childbearing potential must have a negative serum pregnancy test at screening 
 and agree to undergo a urine pregnancy test at , and a serum 
pregnancy test at end of the study . 
6. Females not of childbearing potential will be defined for this study as postmenopausal (defined as cessation of regular menstrual periods for at least 12 months) and confirmed by follicle -stimulating hormone (FSH) level OR surgically sterile  (e.g., total hysterect omy, 
partial hysterectomy, or oophorectomy). 
7. Serum TG criteria  meeting all  of the following criteria : 
a. A historical documented TG ≥400 mg/dL  (4.52 mmol/L)  in the past 5 years from 
screening   or currently on lipid-modifying therapy due to SHTG at  screening  . 
b. Mean of 2 screening fasting serum TG s ≥500 mg/dL (5.65 mmol/L) and ≤2000 mg/dL 
(22.60 mmol/L). The target for the study is 500 mg/dL. D ue to TG variability, up to 
10% of subjects enrolled  may have a mean qualifying TG level between 475  and 
500 mg/dL. Mean screening fasting serum TG is defined as the mean of TG  
 if the average of TG at  is <500 mg/dL, or 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 40 >2000 mg/dL. The repeat measure of TG is permitted at a minimum of 7 days apart at 
.  
c. If 1 of the  2 qualifying TGs is <400 mg/dL, the difference between 2 TG should be 
<300 mg/dL. Note:  If a subject has an individual fasting TG value of <350 mg/dL at 
any one visit or mean of two fasting TG levels <475 mg/dL, they  will be considered a 
screen fail and not eligible to  be re -screened.  
8. Willing to maintain current eating and exercise habits from time of sign ing the informed 
consent and for the duration of the st udy. ( See also Inclusion Criterion #11 and Exclusion 
Criterion #10 regarding alcohol consumption and Exclusion Criterion #4 regarding weight 
changes.)  
9. Concomitant medication may include prescription fish oil (including purified 
eicosapentaenoic acid [ EPA ] with or without docosahexaenoic acid [ DHA ]) and/or statin 
with or without ezetimibe (none of which will be supplied as part of study) as long as the 
subject has been clinically stable (per Principal Investigator [ PI] judgment ) while on stable 
dose for . 
10. Medicines known to exacerbate hypertriglyceridemia (such as certain beta blockers, thiazides, estrogens, bile acid sequestrants) should be stable  
) and remain stable during the study. 
11. Subject is willing to refrain from alcohol consumption for ≥ 48 hours before each study 
visit. 
12. MRI -PDFF of ≥ 6.0% for subjects screened for the fibrate expansion cohort . Note: Those 
who cannot undergo MRI for any reason (e.g., claust rophobia, metal implants ) cannot 
participate in the fibrate expansion cohort. 
5.2. Exclusion Criteria   
Subject s are excluded from the study if any of the following criteria apply:  
1. Females who are pregnant or breastfeeding, or planning to become pregnant, or breastfeed 
while enrolled in the study or within 30 days or 5 half- lives (whichever is longer) after last 
dose of IP .  
2. Uncontrolled or newly diagnosed (< 3 months since diagnosis at time of Screening) 
hypertension . Subjects with well controlled hyperte nsion who are clinically stable may 
enroll if they have been on a stable dose of antihypertensive medications for at least 
2 months before Screening. Subjects who are taking >2 antihypertensive medications may 
be eligible with Medical Monitor (or designee) approval. 
3. Body mass index (BMI) >45 kg/m2 at screening . 
4. Weight change ≥5% in 3 months prior to screening  or weight change ≥5% between 
screening . 
5. Central lab oratory  hemoglobin levels below the lower limit of normal (<12.0  g/dL for 
males , <11.0 g/dL for females), or dialysis, lipid apheresis, plasma exchange, blood 
transfusion, or blood donation/blood loss of ≥400 mL at least a month prior to and during 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 41 the screening period or anticipation of these procedures during the period of the study an d 
up to 30 days afterwards.  
6. A history of symptomatic gallstone disease unless treated with cholecystectomy and/or 
pancreatitis  within 5 years from screening  will be excluded from the study . 
7. ALT  or AST  >3× upper limit of normal (ULN) at screening . 
8. Total bilirubin exceeds ULN at screening , unless prior diagnosis and documentation of 
Gilbert’s syndrome in which case total bilirubin must be ≤3 mg/dL. 
9. Creatine kinase (CK) > 5 × ULN at screening . 
10. Risky drinking (defined as alcohol intake >14 standard drink units per week or 4 standard drinks on a single occasion in men; and alcohol intake >7 standard drink units per week or 3 standard drinks on a single occasion in women) within the 24 months before screening 
 or had positive alc ohol test at screening  . A unit of alcohol is defined as 14 
gram or as 355 mL of beer (5%  alcohol by volume [ABV] ), 1 glass of wine (150 mL; 12% 
ABV), or 1 shot of hard liquor (45 mL; 40% ABV). During the study, subjects will receive 
counseling and will be encouraged to abstain from alcohol. Alcohol intake will be limited to 2 units of alcohol per day for men and 1 unit of alcohol per day for women. Subjects must be willing to abstain from alcohol use 48 hours prior to 
study visits. 
11. Concomitant use of PCSK9 inhibitors, niacin, or any supplements, including 
non-prescription, non- pharmaceutical strength fish oils, used to alter lipid metabolism. 
Previous treatment with a PCSK9 inhibitor will need to have ceased >12 weeks before 
screening w ith no intention to reinitiate treatment for the duration of the trial. Other lipid -
modifying supplements including, but not limited to, red rice yeast supplements, garlic 
supplements, soy isoflavone supplements, sterol/stanol products, or policosanols are not 
permitted.   
a. Subjects participat ing in the main  cohort previously treated with a fibrate will need to 
agree to cease fibrate treatment for the duration of this trial.  
b. Subjects enrolled in the fibrate expansion cohort will need to maintain  their curren t 
stable dose of fibrate therapy  (≥4 weeks before screening ). 
12. Previous long- term (> 4 weeks) use of systemic steroid (glucocorticoid) medications such 
as prednisone within 12 months of screening . Inhaled or topical corticosteroids are 
permitted . 
13. Reduced renal function (eGFR ≤  55 mL/min/1.73  m
2 calculated using chronic kidney 
disease epidemiology collaboration [ CKD- EPI] equation). 
14. Positive for hepatitis B virus ( HBV), hepatitis C virus ( HCV) or human immunodeficiency 
virus ( HIV) . HIV, HBV and HCV determined by antibodies first and, if positive, 
confirmed by DNA/ ribonucleic acid ( RNA).  Subjects who have tested positive for 
COVID-19 who are asymptomatic or who have active COVID -19 infection are excluded . 
Note: subjects who had COVID- 19 and recovered without sequelae or tested positive 
without symptoms at least 8  weeks prior to screening  may be included.  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 42 15. History of substance use disorder, or any other substance dependence (with the exception 
of caffeine) as defined by the Diagnostic and St atistical Manual of Mental Disorders 4th 
edition Text Revision (DSM- IV-TR) in the past 2 years prior to Screening. Subjects 
without a history of substance use disorder who have a positive drug screen test at Screening may be considered for enrollment with Medical Monitor (or designee) approval.  
16. Participation in a previous clinical trial or exposure to another investigational drug within 12 weeks or 5 half- lives, whichever is longer, prior to screening .  
17. Previous exposure to an FGF21 analog 
 
r FGFR1 activating product or known sensitivity to PEG or any of the 
excipients. 
18. Type 1 diabetes mellitus ( T1DM).  
19. Diagnosis of Type 2 diabetes mellitus (T2DM ) <6 months prior to screening .  
20. Subjects with T2DM diagnosed ≥  6 months prior to screening must have a HbA1c < 9.5%  
and if receiving antidiabetic medications, must be on a stable regimen  before screening . A 
stable regimen is defined  as no addition or discontinuation of antidiabetic medications, but 
dose adjustments or switching to another medication in the same class at the same relative 
dose per standard of care are allowed. Insulin , dipeptidyl peptidase IV  (DPP -IV) 
antagonists and other oral medications are allowed if subject has been on a stable regimen 
for at least 3 months. Glucagon- line peptide 1 (GLP -1) agonists and sodium glucose 
co-transporter 2  (SGLT2) inhibitors are allowed if subject has been on stable doses for 
6 months. Use of thiazolidinediones such as pioglitazone, which can reduce serum TGs, are NOT allowed in this study. 
21. History of malignancy within 5 years prior to screening  other than successfully treated 
basal or squamous cell carcinoma or localized cervical carcinoma .  
22. Inadequately controlled thyroid disorders. Subjects on thyroid replacement should be on 
stable doses for at least 2 months prior to screening.  
23. Subjects with known lipoprotein lipase impairment or deficiency (Fredrickson Type 1), 
apolipoprotein C- II deficiency , or familial dysbetalipoproteinemia (Fredrickson Type  3). 
24. Clinically or otherwise documented cardiovascular or cerebrovascular disease including clinically significant anomalies of rhythm or pattern of ECG or New York Heart Association  Class II  to IV heart failure  within 12 months of screening  that, in the 
judgment  of the Investigator, could affect the safety of the subject or their ability to 
comply with the study requirements.  
25. History of bone trauma, fracture , or surgery within 2 months of screening or other bone 
disorders, such as osteoporosis, osteomalacia, and known untreated severe vitamin D deficiency (serum 25 -hydroxy- vitamin D  ≤5 ng/mL) . 
26. Subject who cannot fast for study procedures for any reason per Investigator’s assessment  
will be excluded . Subjects with T2DM who are treated by insulin secretagogues will need 
to consult their treating physician about the optimal timing to take these medications to enable them to fast safely for study procedures.  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 43 27. An employee of the investigational center or has a family member who is involved with 
the conduct of this study. 
28. Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator. 
5.3. Lifestyle Considerations  
Beginning at the screening visit, all subjects will enter a diet, lifestyle, and medication stabilization period . Subjects should maintain their current eating and exercise habits as of the 
time they signed the ICF for the duration of the study. All subjects should be instructed to refrain 
from excessive alcohol consumption.  
5.3.1. Meals and Dietary Restrictions  
Study coordinators should reinforce maintenance of eating and exercise habits without weight loss 
or gain of 5% for the duration of the study, and alcohol consumption restrictions 48 hours prior to 
fasting blood work. All subjects will be required to fast for at le ast 12 hours (it is recommended 
that subjects fast no more than 14 hours) before visits requiring fasted blood sampling . Subjects 
will be instructed to attempt to remain consistent in how long they fast for the duration of the study. For the purposes of this study, fasting is defined as nothing by mouth except non -mineral 
water (and any essential medications).  
5.3.2. Alcohol 
Beginning at the screening visit, all subjects should be instructed to refrain from excessive alcohol consumption, limited to 2 units of alcohol per day for men and 1 unit of alcohol per day for 
women. Subject s will abstain from alcohol for 48 hours before  each study visit. If the subject’s 
alcohol test is positive at a  scheduled visit where lipid panels will be measured, the subject will be 
instructed to come back for an unscheduled visit for lipid panel measurement prior to or at the next 
scheduled visit . 
5.3.3. Activity  
Beginning at the screening visit, all subjects should not alter their normal activity routines  for the 
duration of the study. 
5.4. Screen Failures  
Screen failures are defined as subject s who consent to participate in the clinical study but are not 
subsequently randomized. A minimal set of screen failure information is require d to ensure 
transparent reporting of screen failure subjects to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. 
Minimal information includes demography, screen failure details, eligib ility criteria, and any SAE. 
Individuals who do not meet the criteria for participation in this study (screen failure s other than 
for TGs) may be re -screened, at least 7 days later, if the reason for screen failure is deemed 
temporary and is resolved prior to re -screening ( e.g., high blood pressure). Re-screened subjects 
will sign a new consent and be assigned a new ID. Subjects can only re- screen once.  Re-screening 
subjects who have maintained the lifestyle stabilizati on period may be allowed to forgo repeated 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 44 tests  at the discretion of the Medical Monitor. Re -screening after COVID -19 
infection requires Medical Monitor approval.  
Retesting of laboratory tests is allowed when results are deemed spurious or i ncomplete.  
6. INVESTIGATIONAL PRODUCT
Investigational product is defined as BIO89 -100 or matching placebo, intended to be administered 
to a study subject according to the study protocol. 
6.1. Investigational Product(s) Administered 
Investigational product will be administered SC to the abdomen by qualified study personnel. 
Each admi nistration will consist of 2 SC injections.  
Arm Active arm  Placebo arm (control)  
Intervention BIO89-100 Matching Placebo 
Type Biologic Chemical solution  
Dose 
Formulation  
 
   
 
 
Unit Dose Strength(s)  Mg Not applicable 
Dosage Level(s)a 9 mg, 18 mg, 27 mg QW 
36 mg Q2W  NA; matching placebo will be injected at matching frequency per protocol . 
Route of Administration SC injection  SC injection  
Sourcing  Provided centrally by 89bio Provided centrally by 89bio 
Packaging and Labeling  BIO89-100 is supplied as a sterile, 
preservative-free, frozen liquid 
formulation in a single -use Type 1 clear 
glass vial for SC injection. Each vial will 
be labeled as required  per country 
requirement.  Placebo will be supplied as a sterile, 
preservative-free, frozen liquid formulation in a single -use Type 1 clear 
glass vial for SC injection. Each vial will be labeled as required per country requirement.  
Abbreviations: QW = every week; Q2W  = every 2 weeks. 
a The actual doses will be ±5% the mg dose due to technical considerations related to drug withdrawal from the vials 
into the syringes for injection. This difference is considered negligible for subject  exposure.  
6.2. Admin istration Instructions  
On-site administration : The SC injection of the IP  should be performed by a limited number of site 
staff specifically trained in the administration of SC injections. Injections will be administered in 
the abdominal area only. Details on injection of IP will be provided in the relevant study manual. 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 45 After administration of the IP , the subject should remain resting  for ~15 minutes. For additional 
doses in the same subject, the injection site should be rotated within the abdominal area by at least 
2 inches. Injections should be at least 2 inches from the umbilicus (belly button). 
Home administration : Home administration of IP may occur on . 
Home health visits conducted by qualified HHPs  for IP dosing will follo w the above 
administration protocol. Further details are provided in the relevant study manual.   
6.3. Preparation/Handling/Storage/Accountability  
BIO8 9-100 will be stored and prepared in  appropriate conditions as indicated in the relevant study 
manual. 
• The Investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all IP  received and any discrepancies are reported 
and resolved before use of the IP . 
• Only subjects enrolled in the study may receive IP  and only authorized study staff or 
HHPs  may supply or administer IP . All IP on site  must be stored in a secure, 
environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions , with access limited to the  Investigator and 
authorized site staff.  
• The Investigator, institution, or the head of the medical institution (where applicable) is responsible for on-site IP accountability, reconciliation, and record maintenance (i.e., 
receipt, reconciliation, and final disposition records).  
• Further guidance and information for IP  shipping, preparation, and administration and 
the final disposition of unused IP s are provided in the relevant manuals for on- site and 
home administration . 
6.4. Measures to Minimize Bias: Randomization and Blinding  
Eligible subject s will be randomized in the order they are enrolled into the study. Subjects in the 
main  cohort will be randomized in a 1:1:1:1:1  ratio to  1 of 4 doses of BIO89-100 (9 mg QW, 
18 mg  QW, 27 mg QW, or 36 mg Q2W) or placebo. Subjects in the fibrate expansion cohort will 
be randomized in a 1:1 ratio to BIO89-100 27 mg or placebo QW. 
To maintain the blind, each subject will receive 2 injections QW including subjects randomized to 
36 mg Q2W who will receive placebo injections at alternate Q2W visits . 
Randomization in the main cohort will be stratified by TG <750 mg/dL or ≥750 mg/dL 
(8.47 mmol/L) and by whether or not the subject is receiving background therapy (e.g., 
prescription fish oil and/or statins ). Randomization in the fibrate expansion cohort will be 
stratified by TG <750 mg/dL or ≥750 mg/dL (8.47 mmol/L) only. All subjects will be centrally 
assigned to randomized IP using an Interactive Voice/Web Response System (IVRS/IWRS). 
Before the study is initiated, the log-in information and directions for the IVRS/ IWRS will be 
provided to each site.  
The study will be conducted under double- blind conditions. The subject s, PI , other study 
personnel involved with subject assessments, and 89bio will remain blinded to the actual treatment 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 46 assignments of the subject s, post- baseline lipid panels  (TG, , LDL -C, HDL -C, Non -HDL -C, 
VLDL -C, V LDL -TG, , ApoB, , RPL- C, ), , and PK data. Blinded IP  will 
be provided by a clinical supplies vendor and shipped to the study site. IP  may be delivered to the 
subject’s home  for home administration by an HHP. The SC administration of the blinded IP  will 
be performed  by trained study staff, and only blinded staff will be involved with subject 
assessments. 
6.5. Emergency Unblinding  
At the initiation of the study, Investigators will be instructed on the method for breaking the blind. 
The method will be an electronic process in the IWRS /RTSM  system . Blinding codes should be 
broken only in exceptional circumstances when knowledge of the actual treatment code is 
essential for furth er management of the subject. Investigators are encouraged to discuss with the 
Medical Monitor if they believe that unblinding is necessary. When the blinding code is broken, the reason must be fully documented and subject will need to discontinue study drug and complete the final study procedures.  
6.6. Investigational Product Compliance  
The date and time of each dose administered in the clinic will be recorded in the source documents and recorded in the electronic case report form (eCRF). The dose of IP  and study subject  
identification will be confirmed by a member of the study site staff other than the person administering the IP . For doses administered by an HHP, administration details will be provided to 
the study staff for documentation. 
In cases in which a dose is administered outside of the allowed visit time window, adjustments to 
the remaining visit dates may be required. The Investigator should discuss with the Medical 
Monitor if the dosing schedule changes markedly compared to the original schedule. 
6.7. Concomitant Therapy  
Any medication or vaccine (including over- the-counter or prescription medicines, vitamins, and/or 
herbal supplements) or other specific categories of interest that the subject  has received within 
3 months from Screening   (prior therap y), is receiving at the time of enrollment, or receives 
during the study must be recorded along with: 
• Reason for use 
• Dates of administration including start and end dates  
• Dosage information including dose and frequency 
The Medical Monitor should be contacted if there are any questions regarding concomitant or 
prior therapy. 
Concomitant medication may include prescription fish oil (including purified EPA with or without 
DHA) and/or statin with or without ezetimibe (none of which will be supplied as part of s tudy) as 
long as the subject has been clinically stable (per PI judg ment ) while on s table dose for ≥4 weeks 
before screening  and will maintain stable dose during the duration of the study. 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 47 Elevated levels of FGF21 have been linked to reduced cytoch rome P450 3A (CYP3A) mRNA 
expression and activity in NAFLD patients ( Woolsey et al, 2016). The underlying mechanism has 
not been fully elucidated and whether such effects  will be observed in SHTG patients is unknown. 
However , subjects receiving concomitant  administration of CYP3A4 substrates with narrow 
therapeutic index should be closely monitored for any potential ly related  safety event s, and dose 
adjustment of the  CYP3A4 substrate should be considered as needed . 
COVID -19 vaccine, if available, will be allowed  but s ubjects are prohibited from participat ion in 
interventional COVID- 19 vaccine clinical trials.    
6.7.1. Prohibited Medications/Therapies  
Subjects must abstain from taking lipid -modifying supplements after the start of screening until 
completion of the EOS visit, unless, in the opinion of the I nvestigator and  the M edical Monitor , 
the medication is required.  
Other prohibited therapies include: 
• Use of PCSK9 inhibitors, niacin, or any supplements, including non- prescrip tion, non-
pharmaceutical strength fish oils, used to alter lipid metabolism.  For subjects enrolled 
in the main  cohort, use of fibrates is prohibited. 
• Medicines known to exacerbate hypertriglyceridemia (such as certain beta blockers, 
thiazides, estrogens, bile acid sequestrants) should be stable (≥4 weeks before 
screening  and remain stable during the study. 
• Other lipid -modifying supplements incl uding, but not limited to, red rice yeast 
supplements, garlic supplements, soy isoflavone supplements, sterol/stanol products, or policosanols. 
• Long- term (>4 weeks) use of systemic steroid (glucocorticoid) medications such as 
prednisone. Inhaled and topical steroids are acceptable.  
• Use of thiazolidinediones such as pioglitazone  
• Any IP , FGF21 analog
 
or FGFR1 act ivating product . 
6.7.2. Blinded Alerts and Rescue Medications/Therapies  
Lipid panel results including T G are blinded during the study. I f a subject  has a measured fasting  
TG >2000 mg/dL, a blinded alert will be sent to the Investigator not ing that the TG alert criteria 
has been met for that subject. The Investigator  will contact the subject for the following: 
• Investigator to c onfirm and ensure the subject is managed and compliant with the 
allowed standard of care therapies for optimal hypertriglyceridemia  management . 
• Investigator to confirm t he subject was fas ting for at least  12 hours and was absent 
from alcohol for 48 hours prior to the TG triggered blinded alert was measured . 
• Investigator to schedule t he subject for an unscheduled fasting TG measurement. The 
subject should fast for at least  12 hours (and recommended no more than 14 hours) and 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 48 have no alcohol 48 hours prior to the planned unscheduled visit TG measurement . The 
subject should have the unscheduled fasting TG measurement prior to or at the next 
scheduled visit.  
If the subject has 2 consecutive blinded TG alert s, the Investigator should assess whether it is 
clinically safe for the subject to continue receiving IP. 
6.8. Stopping Rules  
The Sponsor may suspend or terminate the study in the event of: 
• New toxicological or pharmacological findings or clinical safety findings that 
invalidate the earlier positive benefit -risk assessment;  
• Discontinuation of the development of BIO89 -100; 
• External circumstances that do not enable the study to be properly conducted under the 
existing protocol, including potential circumstances related to the COVID-19 pandemic. 
6.8.1. Monitoring and Discontinuation for  Suspected Drug -induced Liver Injury (DILI)  
Criteria  
A subject will be additionally monitored if they meet any of the following liver- related c riteria.  
Baseline value is defined as the last ALT and AST values performed prior to or on the  
. 
New transaminase elevations in subjects with baseline value within the normal rang e:  
For new elevations  in transaminases greater  than 2 × ULN, repeat measurement should be 
performed within  48 to 72 hours. If elevations persist, subjects should be evaluated for 
other causes of transaminase elevations and with tests of hepatic function. If no other  cause 
is identified,  then the subjects need to be monitored  closely (see below), and 
discontinuation of the study drug should be considered.  
Drug should be discontinued, and the subject followed until resolution of symptoms or 
signs in the following situations:  
• ALT or AST >8 × ULN  
• ALT or AST >5 × ULN for more than 2 weeks  
• ALT or AST >3 × ULN and (TB >2 × ULN or INR >1.5)  
• ALT or AST >3 × ULN with the appearance of fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)  
New transaminase elevations in subjects with baseline ALT or AST > U LN:  
For new elevations  in transaminases greater  than 2 × baseline value or total bilirubin 
>1.5× ULN, repeat measurement should  be performed within  48 to 72 hours. If elevations 
persist, subjects should be evaluated for other causes of  transaminase elevations and with 
tests of hepatic  function. If no other  cause is identified,  then the subjects need to be 
monitored closely (see below), and discontinuation of the study drug should be considered. 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 49 Drug should be discontinued and the subject followed until resolution of symptoms or signs in the 
following situations described in  Table 3 : 
Table  3: Discontinuation Criteria in Subjects with Abnormal Baseline ALT or AST 
Values  
Baseline  value of ALT/AST  Criteria to discontinue investigational product  
<2× ULN  if ALT or AST increases to >5 × baseline value 
≥2× ULN but <5× ULN  if ALT or AST increases to >3 × baseline valu e 
≥5× ULN  if ALT or AST increases to >2 × baseline value 
Other  if ALT or AST increase >2 × baseline value AND the increase is 
accompanied by a concomitant total bilirubin increase to 
>2× ULN OR the INR concomitantly increases by >0. 2  
if ALT or AST increase >2 × baseline value in the presence of 
signs and symptom(s) such as fatigue, nausea, vo miting, right 
upper quadrant pain or tenderness, fever, rash, and/or eosinophil (>5%)  
ALT = alanine aminotransferase; AST = aspartate aminotransferase; INR = International Normalized ratio; 
ULN = Upper limit of normal  
Close monitoring for suspected DILI includes: 
• Repeating liver enzyme and serum bilirubin tests 2 or 3 times weekly. Frequency of 
repeat testing can decrease to once a week or less if abnormalities stabilize or the trial 
drug has been discontinued and the subject is asymptomatic. 
• Obtaining a more detailed history of symptoms and prior or concurrent disease s. 
• Obtaining a history of concomitant drug use (including non- prescription  medications 
and herbal and dietary supplement preparations), alcohol use, recreational drug use, and special diets.  
• Ruling out acute viral hepatitis types A, B, C, D, and E, autoimmune or alcoholic 
hepatitis , hypoxic/ischemic hepatopathy; and biliary tract disease.  
• Obtaining a history of exposure to environmental chemical agents. 
• Obtaining additional tests to evaluate liver function, as appropriate (e.g., INR, direct bilirubin).  
• Considering gastroenterology or hepatology consultations. 
Note: If a subject  lives in a remote area, laboratory testing can be performed locally, and the 
results should be promptly communicated to the I nvestigator site.  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 50 7. INTERRUPTION OR DISCONTINUATION OF
INVES TIGATIONAL PRODUCT  AND SUBJECT
DISCONTINUATION/WITHDRAWAL
7.1. COVID- 19-Related Risk Mitigation and Interruption of
Investigational Product Administration
The following are provided as mitigations in the event of potential disruptions to study conduct 
secondary  to COVID-19 infection or related control measures:  
•Dose interruption resulting in missing 1 dose is acceptable at any time during the
dosing period.
•Interruption in IP administration and other study procedures (collectively “study
interruption”) will be allowed for up to 2 weeks up to Week 5.
•Dose interruption for 2 weeks after Week 5 is not allowed  and will require
discontinuation of treatment as resuming the dose would impact the interpretation ofthe primary endpoint .
•Study interruptions longer than 2 weeks at any time during the dosing period will lead
to discontinuation of treatment and the subject’s participation in the study.
•For subjects who have a study interruption, prior to resuming dosing, the Investigator
will assess whether the subject is clinically stable to continue participation in the study
and will discuss the assessment with the Medical Monitor.
•Upon resumption of dosing, the subject will continue at the next planned visit relativeto the last visit performed prior to study interruption and will be administered all
remaining planned doses.
•If clinical laboratory tests are not part of the protocol- defined procedures for the first
dosing visit after study interruption, unscheduled hematology and clinical biochemistrypanels may  be obtained prior to dosing as needed and at Investigator discretion  and
sent to the central lab. Results from both local and central labs should be documented
in EDC.
•If circumstances related to the COVID -19 pandemic or other extenuating
circumstances preclude a visit to the investigative site, a lternative  means for
completing study procedures  and assessments may  be considered  at Investigator
discretion , in accordance with local guidance/regulations and with Medical Monitor
approval . For example , remote verification of source data may be instituted . Also,
safety  assessments may be conducted via telemedicine or phone contact or laboratory
tests may be obtained at a certified local lab.  Local analysis can be used for safety
decisions.
Efforts should be made to obtain EOT  assessments in subjects who are not willing  or able  to return 
to the study after study interruption, who are deemed not clinically stable to continue participation 
by the Investigator, or who are lost to the study due to disruptions because of the COVID-19 
pandemic. The EOT  visit should be scheduled as soon as possible in these scenarios, whenever 
possible.  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 51 • Study interruption will be allowed as long as COVID-19 pandemic- related 
circumstances are ongoing and will not be allowed when these circumstances are  no 
longer applicable, as determined by the Sponsor. 
• For newly qualified  subjects who have not yet received their first dose at a site and that 
can foresee a near -term disruption by the COVID- 19 pandemic, the Investigator should 
discuss with the Sponsor whether the initiation of dosing should be postponed. In this 
situation, study interruption should not apply, and the subject will initiate and finish all planned doses when the Investigator deems it is safe to start dosing. Re-screening or 
retest of certain laboratory tests may be required prior to start of dosing, pending 
Medical Monitor evaluation.  
Changes in study visit schedules, missed visits, or patient discontinuations may lead to missing information (e.g., for protocol-specified procedures). Specific information will be captured in the 
eCRF  that explains the basis of the missing data, including the relationship to COVID -19 for 
missing protocol-specified information (e.g., from missed study visits or study discontinuations 
due to COVID-19). 
7.2. Discontinuation of Investigational Product 
In rare instances, it may be necessary for a subject  to permanently discontinue IP. If IP  is 
permanently discontinued, subject s will be requested to have an EOT visit within 7 days of 
terminating the treatment and an EOS  visit 4 weeks later. The subject will remain in the study to 
be evaluated for safety tolerability, and PK/PD assessments. The reason for subject withdrawal from the IP will be recorded in the eCRF. See the SoA ( Table  2) for data to be collected at the 
time of discontinuation of IP  (EOT visit).  
7.3. Subject Discontinuation/ Withdrawal from the Study  
A subject  may withdraw or be withdrawn from the study for the following reasons:  
• Investigator decision  
• AE or intercurrent illness  
• Noncompliance with protocol requirements 
• Subject ’s withdrawal of consent  
• Sponsor termination or suspension of the study 
• Lost to follow -up 
• A COVID-19- related dose interruption for 2 weeks or longer after  or 
study interruptions longer than 2 weeks at any time during the dosing period 
The reason for subject ’s withdrawal from the study will be recorded in the eCRF.  
At the time of withdrawal from the study, subject s will be requested to have an EOT visit within 
7 days of terminating the treatment, and an EOS  visit 4 weeks later, as shown in the SoA ( Table 
2). 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 52 7.4. Lost to Follow -up 
A subject will be considered lost to follow -up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study site. 
The following actions must be taken if a subject fails to return  for a required study visit: 
• The site must attempt to contact the subject and reschedule the missed visit as soon as 
possible and counsel the subject on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the subject wishes to and/or should continue in 
the study. 
• Before a subject is deemed lost to f ollow -up, the I nvestigator or designee must make 
every effort to regain contact with the subject (where possible, 3 telephone calls and, if necessary , a certified letter to the subject’s last known mailing address or local 
equivalent methods). These contact attempts should be documented in the subject’s medical record . 
• Should the subject continue to be unreachable, he/she will be considered to have 
withdrawn from the study .  
Discontinuation of specific sites or of the study is handled as part of Appendix 1 ( Section  10.1.8). 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 53 8. STUDY ASSESSMENTS AND PROCEDURES  
• Study procedures and their timing are summarized in the SoA ( Table  2). Protocol 
waiver s or exemptions are not allowed. 
• All screening evaluations must be completed and reviewed to confirm that potential 
subjects meet all eligibility criteria. The Investigator wi ll maintain a screening log to 
record details of all subjects screened and to confirm eligibility or record reasons for screening failure, as applicable.  
• If multiple assessments are scheduled at the same timepoint, it is recommended that procedures be perf ormed in the following sequence: 12- lead ECGs, vital signs, sample 
collection for lipids, other laboratory and PD biomarker tests, sample collection for PK  
and , prior to administration of study drug. 
• Immediate  safety concerns should be discussed with study M edical Monitor 
immediately upon occurrence or awareness to determine if the subject should continue 
or discontinue IP . 
• Adherence to the study design requirements, including those specified in the SoA 
(Table 2 ), is essential and required for study conduct. 
• Procedures conducted as part of the subject’s routine clinical management (e.g., blood 
count) and obtained before signing of the ICF may be utilized for subject  management 
and pre-screening, however screening and baseline assessments must be obtained by central lab oratory and as defined by the protocol . 
• Any situation at the site level with potential impact on subject safety or study conduct, including situations related to COVID-19 infection or control measures, should be discussed with the S ponsor/ contract research organization ( CRO ) immediately upon 
occurrence or awareness to determine potential impact on study subject/s or study conduct. 
8.1. Efficacy Assessments  
Fasting blood samples will be collected at the ti me points specified in the SoA for the 
measurement of serum total lipids, lipoprotein  profile s, and apolipoproteins. Efficacy assessments 
in this study are the PD and biomarker assessments, which are describ ed in Section  8.6. 
8.2. Safety Assessments  
Safety assessments include AEs (either reported by the subject or observed by the Investigator), 
concomitant medication use, physical examination, ECG, vital signs, and laboratory assessments. 
Any clinically significant safety assessment  findings, including physical examination, ECG, vital 
signs, laboratory assessments, and  AEs that are considered to be related to COVID-19 infection 
should be documented as such in the AE term reported (e.g., COVID-related pneumonia).  
All safety analyses will be performed using the Safety Analysis Set  (Section  9.4.5). Planned time 
points for all safety assessments are provided in the SoA (Table 2 ). 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 54 8.2.1. Physical Examinations  
• A complete physical examination will include, at a minimum, assessments of the 
cardiovascular, respiratory, abdominal and a neurological exam. Height (only collected at screening) and weight will also be measured and recorded.  
• A symptom directed physical examination will include, at a minimum, assessments of 
the skin, respiratory, cardiovascular sys tem, and abdomen (liver and spleen). 
8.2.2. Vital Signs  
• Vital signs including body temperature, pulse rate, RR, and supine BP  will be assessed.  
• Planned time points for vital signs assessment  are provided in the SoA ( Table  2). 
• Starting from randomization, BP  and pulse will be measured in duplicate . The first 
measurement will be initiated before dosing with sitting/semi -erect or supine position 
and resting for at least 5 minutes prior to measurements. BP and pulse are to be 
repeated at least 1 minute apart . Additional vital signs measurement may be done if 
clinically indicated.  
8.2.3. Electrocardiograms  
• 12-lead ECG will be recorded as single bedside measurements using an ECG machine 
that automatically calculates the heart rate and measures PR, QRS, and QT (QTcF) 
intervals.  
• Subject to be resting for at least 2 minutes prior to ECG.  
8.2.4. Clinical Safety Laboratory Assessments  
• See Appendix 2 (S ection  10.2) or the list of clinical laboratory tests to be performed 
and the SoA ( Table 2 ) for the timing and frequency.  Laboratory tests should be 
performed under fasting conditions ( for at least 12 hours ; it is recommended that 
subjects fast no more than 14 hours ). Subjects should be instructed to attempt to remain 
consistent in how long they fast prior to blood draws for the duration of the study. 
• Fasting is defined as taking nothing by mouth except non- mineral water (and any 
essential medications).  It is required  that subject s abstain from consumption of 
alcoholic beverages for at least 48 hours before laboratory test assessments.  
• The Investigator must review the laboratory report, document this review, and record 
any clinically relevant changes occurring during the study in the AE section of the eCRF. The laboratory reports must be filed with the source documents. Clinically 
significant abnormal laboratory findings are those which are not associated with the 
underlying disease, unless judged by the Investigator to be more seve re than expected 
for the subject’s condition. 
• Retesting  of laboratory tests is allowed when results are deemed spurious or 
incomplete . 
• All laboratory tests with values considered clinically significantly abnormal during 
participation in the study or within  28 days after the last dose of IP  should be repeated 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 55 until the values return to normal or baseline or are no longer considered clinically 
significant by the Investigator or the Medical Monitor.  
• If such values do not return to normal/baseline within a period of time judged reasonable by the Investigator and remain clinically significant, the etiolo gy should be 
identified and the M edical Monitor notified.  
• All protocol -required laboratory assessments, as  defined in Appendix 2 ( Section  10.2), 
must be conducted in accordance with the relevant study manual and the SoA (Table  2). 
• If laboratory values from non -protocol specified laboratory assessments performed at 
the institution’s local laboratory require a change in subject management or are considered clinically significant by the Investigator (e.g., SAE or AE or skipping of 
dose), then the results must be reco rded in the eCRF and the M edical Monitor should 
be notified. 
8.3. Adverse Events and Serious Adverse Events 
The definiti ons of an AE or SAE can be found in Appendix 3 ( Section  10.3).  
Adverse events will be reported by the subject (or, when appropriate, by a caregiver, surrogate, or 
the subject ’s legally authorized representative).  
The Investigator and any qualified designees are responsible for detecting, documenting, and recording events that meet the definition of an AE or SAE a nd remain responsible for following 
up AE s that are serious, considered related to the IP  or study procedures, or that caused the subject  
to discontinue the study or IP  (see Section  7). 
8.3.1. Time Period and Frequency for Collecting AE and SAE Information 
The timing and frequency of collection of a ll AEs  and SAEs is  specified in the SoA ( Table 2 ). 
Table 4 summarizes the different reporting periods for AEs , SAEs and events to monitor. Events 
to monitor are defined in Section  10.3.3. 
Table  4: Adverse Event Reporting Periods 
Type of 
Event  Adverse Event Serious Adverse Event  Events to M onitor with 
Investigational Product 
Reporting period  From consent until 28 days after last dose of 
investigational product  From consent until 28 days after the last dose of investigational product   From consent until 28 days after the last dose of investigational product  
Reporting Timelines to  
89bio   Entered into the clinical database on an ongoing basis  Within 24 hours  Within 24 hours  
All SAEs will be recorded and reported to 89bio or designee immediately and under no 
circumstance should this exceed 24 hours, as indicated in Appendix 3 ( Section  10.3). The 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 56 Investigator will sub mit any updated SAE data to 89bio or designee within 24 hours of it being 
available.  
Investigators are not obligated to actively seek AEs  or SAEs after conclusion of the study 
participation. However, if the Investigator learns of any SAE, including a death, at any time after a 
subject has been discharged from the study, and he/she considers the event to be reasonably 
related to the IP or study participation, the Investigator must promptly notify  89bio or designee. 
8.3.2. Method of Detecting AEs and SAEs  
The method of recording, evaluating, and assessing causality of AEs  and SAEs and the procedures 
for completing and transmitting SAE reports are provided in Appendix 3 ( Section  10.3).  
Care will be taken not to introduce bias when detecting AEs  and/or SAEs. Open-ended and 
non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrences. 
8.3.3. Follow- up of  AEs  and SAEs  
After the initial AE/SAE report, the Investigator is required to proactively follow each subject at 
subse quent visits/contacts. All SAEs  will be followed until resolution, stabilization, the event is 
otherwise explained, or the subject is lost to follow -up (as defined in Sectio n 7.4) . Further 
informa tion on follow -up procedures is provided in Appendix 3 ( Section  10.3). 
8.3.4. Regulatory Reporting Requirements for SAEs 
• Prompt notifica tion by the Investigator to 89bio or designee of an SAE is essential so 
that legal obligations and ethical responsibilities regarding  the safety of subjects and 
the safety of the IP  under clinical investigation are met.  
• 89bio has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of the IP  under clinical investiga tion. 89bio will 
comply with country- specific regulatory requirements relating to safety reporting to the 
regulatory authority, IRBs /IECs , and Investigator s. 
• Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (SUSARs) according to local regulatory requirements and 89bio policy and 
forwarded to Investigators as necessary.  
• An Investigator who receives an Investigator S afety Report describing an SAE or other 
specific safety information (e.g., summary or listing of SAEs) from 89bio will review and then file it along with the IB and will notify the IRB/IEC, if appropriate according to local requirements.  
8.3.5. Pregnancy  
• Details of all pregnancies in female subjects and in  female partners of male subject s 
will be collected after the start of IP  and until 90 days after last dose of IP. 
• If a pregnancy is reported, the Investigator should inform 89bio within 24 hours of 
learning of the pregnancy and should follow the procedures outlined in Appendix 4 
(Section  10.4).  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 57 • Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs.  
8.4. Treatment of Overdose  
There is no experience with overdose of BIO89-100 in humans. 
For this study, any dose of BIO89-100 greater than the protocol-specified dose will be considered 
an overdose. 
89bio does not recommend specific treatment for an overdose.  
In the event of an overdose, the Investigator should: 
1. Contact t he Medical Monitor immediately.  
2. Monitor the subject ’s vital signs and institute supportive measures as indicated by the 
subject’s clinical state.  
3. Obtain a plasma sample for PK analysis within 2 days from the date of the overdose if 
requested by the Medical Monitor (determined on a case -by-case basis).  
4. Document the quantity of the excess dose as well as the incidence of the overdose in the 
eCRF.  
8.5. Pharmacokinetics  
Blood samples for analysis of BIO89- 100 serum levels will be collected at the timepoints 
designated in the SoA ( Table  2). 
Blood samples will be processed for collection of serum fractions for determination of BIO89 -100 
serum concentrations. BIO89 -100 metabolites may be analyzed. Serum samples will be shipped to 
the bioanalytical laboratory for analysis.  
The trough serum BIO89-100 concentrations will be summarized by treatment group and nominal 
sampling time using descriptive statistics.  
When appropriate, pharmacokinetic parameters calculated by non- compartmental methods from 
the BIO89 -100 serum concentration data will include: 
• Cmax 
• AUC 0-tau 
• tmax 
• t½ 
Subject s may choose to participate in the Intensive PK scheme. All subjects will be included in the 
Trough PK scheme. Table  5 details sampling times for the I ntensive PK scheme. For subjects in 
the Trough PK scheme, blood samples will be taken within 4 hours prior to dosi ng on specified 
dosing days or during EOT visit . 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 58 Table  5: Intensive PK S cheme for Sample Collection  
Note: Where the Intensive PK schedule overlaps with the Trough PK schedule, only 1 PK 
measurement should be taken at those timepoints. 
Additional PK parameters may be calculated if deemed appropriate.  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 59 8.6. Pharmacodynamics and Biomarkers  
8.6.1. Pharmacodynamics 
The following biomarkers/PD parameters will be evaluated at timepoints designated in the SoA 
(Table  2). 
Laboratory parameters : 
• TG 
•  
• VLDL -C 
• VLDL -TG 
• LDL -C 
• HDL -C 
• Non- HDL -C 
• ApoB 
• RLP-C 
•  
•  
•  
•  
•   
• ALT  
• AST  
• Adiponectin 
• hsCRP  
•  
•  
•  
Samples may be stored for a maximum of 15 years after the last subject ’s last visit for the study , at 
a facility selected by 89bio, to enable further analysis of biomarker responses to BIO89 -100. 
Residual blood samples will be stored for potential future analysis of biomarkers.  
Additional information will be available in the study -specific laboratory manual.  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 60 Other parameters include:  
• Imaging measures ( Section  8.6.3) 
− MRI -PDFF  
• Anthropomorphic measurements  
− Body weight 
− BMI  
−  
−   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.6.3. Magnetic Resonance Imaging – Whole Liver Proton Density Fat Fraction  
MRI -PDFF is a non- invasive, quantitative, and accurate measur e of liver fat content 
(imaging -based biomarker) to assess trea tment response in clinical studies  (Caussy, et al. 2018). 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 61 This technology enables post- processing of MRI data into a parametric map of Proton Density Fat 
Fraction  (PDFF; Antaros Medical, Sweden) to provide accurate and quantitative measures of liver 
fat.  
The PDFF is determined using a 6-echo gradient echo pulse sequence covering the liver in the 
axial plane. Analysis is performed by semi -automatic contouring of the liver in every slice 
avoiding major vessels and bile ducts. The method appl ies multi -peak lipid spectral models and 
simultaneous quantification and correction for T2 (refer to the Imaging Manual for more information) . The liver fat value (PDFF) is the mean value of all voxels in the identified volume of 
intere st.  
After a consenting subject’s , the site should preemptively schedule the baseline MRI- PDFF to 
occur within the following projected visit windows to ensure an MRI appointment is available to 
be performed after the  TG result ≥350 mg/dL is known. Fo r the main cohort, MRI -PDFF is 
optional and should occur prior to  (The study aims to enroll ~33% of subjects 
[~30 subjects total] in the main cohort w ith a baseline MRI -PDFF ≥ 6.0% .) For the fibrate 
expansion cohort, MRI- PDFF of ≥ 6.0% is requir ed for enrollment and should be performed 
between   The follow-up MRI at  should only be 
performed if the baseline liver MRI- PDFF value is ≥ 6.0%. MRI -PDFF is mandatory in the fibrate 
expansion cohort. 
 
 
8.6.4. Exploratory Analyses 
  
 
 
 
 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 62 9. STATISTICAL CONSID ERATIONS  
9.1. Statistical Hypotheses  
The study hypothesis is that BIO89-100 can significantly improve efficacy parameters and is well 
tolerated for subject s with SHTG.  
The hypotheses for the primary endpoint are: 
• Null hypothesis: treatment with BIO89 -100 and pl acebo  result in  the same percentage 
change in serum TG from baseline to Week  8 
• Alternative hypothesis: treatment with BIO89 -100 and placebo result in significantly 
different perce ntage changes in serum TG from baseline to Week  8 
The null hypotheses will be tested at significance level of 0.05 ( 2-sided) for each BIO89 -100 
treatment group versus placebo. 
9.2. Sample Size Determination  
The effect of BIO89 -100 on the percentage change from baseline in TG is estimated based on 
prior clinical studies  evaluating BIO89- 100 and other TG lowering agents:  
 
 
 
 
 
 
 
 
Based on these results, it is estimated that the SD of the percent change in TG at Week  8 is ~ 40%. 
With 18 subject s in the placebo group and each BIO89-100 dose group, there would be at leas t 
86% power to detect a 45% difference in TG between each BIO89-100 dose group and placebo at 
the 2-sided alpha level of 0.05, assuming 50% reduction in BIO89- 100 dose group and 5% in the 
placebo group.  
Fatty liver has been shown to be significantly associated with moderately severe or severe acute 
pancreatitis  (Yoon, et al. 2017). Hence, another focus of th is study is to assess the BIO89 -100 
effect on reducing liver fat as assessed by MRI -PDFF in the SHTG population, with or without 
concurrent stable fibrate therapy. In Study BIO89-100-002 (Part 1), BIO89-100 (27 mg QW) reduced liver fat as assessed by MRI -PDFF up to 60%. In the main cohort not on concomitant 
fibrate therapy , a sample size of ~30 subje cts (e.g., ~33% of the main cohort total sample size, 
~6 placebo vs ~24 pooled BIO89-100) is estimated to provide ~89% power to detect a difference 
of at least 50% mean percentage reduction in MRI -PDFF at Week 8 compared to placebo, using a 
significance level of 0.05 (2- sided). These calculations are based on an assumption that the 
percentage change from baseline in MRI -PDFF is normally distributed with a standard deviation 
of no greater than 30%, as estimated from data in Study BIO89-100-002. In the fibrate expansion 
cohort, assuming a difference of 50% mean percentage reduction in MRI -PDFF at Week 8 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 63 compared to placebo, a standard deviation of no greater than 30% under normal assumption, and a 
significance level of 0.05 ( 2-sided), the planned sample size of 18 subjects per group will have 
>99% power to detect such a mean difference.  
This sample size assessment incorporates approximate ly 10% of subjects lost to follow -up. 
9.3. Populations for Analyses  
The following populations are defined for the main and fibrate expansion cohort s. 
Population  Description  
Screened Analysis 
Set All subject s who signed informed consent and have undergone screening.  
Randomized Analysis Set  All subject s in screened analysis set who are assigned a randomization number in 
the study.  
Full Analysis Set All randomized subject s who received at least 1 dose of IP , have a baseline, and at 
least 1 post-baseline efficacy measurements. 
Safety Analysis Set  All subject s who received at least 1 dose of IP. 
Intensive PK Analysis Set  All subject s in the Safety Analysis Set , who opt ed to participate in the Intensive 
PK scheme,  and have at least  1 on-study PK measurement.  
MRI-PDFF Analysis Set  All subject s in the F ull A nalysis Set who  have MRI -PDFF at baseline and a post -
baseline assessment. 
9.4. Statistical Analyses  
The analyses presented here represent an outline of the intended methodology. Changes, additions, 
and further details about the analyses will be described in the statistical analysis plan (SAP), as applicable. The SAP will be developed and finalized before database lock and will describe the 
subject populations to be included in the analyses, and procedures for accounting for missing, unused, and spurious data.  
Subjects with dose interruptions affected  by the COVID-19 pandemic will be noted in the listings. 
The i mpact on COVID-19 related study interruption may be considered, as appropriate. 
9.4.1. General C onsiderations 
In general, summaries and analyses will be presented by dose/treatment group and by cohort . 
Descriptive statistics will be presented for demographics and baseline characteristics, safety 
endpoints, and PK and PD parameters. Continuous variables will be summarized by number of 
subject s and mean, SD/standard error, median, minimum, and maximum va lues. Categorical 
variables will be summarized by number and percentage of subject s. 
The analyses will be performed separately for the main cohort and the fibrate expansion cohort.  
All primary, secondary , and exploratory efficacy endpoints will be assessed in the Full Analysis 
Set. All safety assessments will be performed on the Safety Analysis Set. PK endpoints will be 
assessed in the Intensive PK  Analysis Set as applicable. Endpoint s of M RI-PDFF will be assessed 
in MRI -PDFF Analysis Set.  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 64 All statistical tests will be  2-sided and tested at a statistically  significant level of 0.05 without 
adjustment for multiplicity. Confidence intervals will be 2 -sided 95%, unless stated otherwise.  
9.4.2. Primary E ndpoint(s)  
The primary efficacy analysis of the primary endpoint, percentage change in serum TGs from 
baseline to Week  8, will be performed using the Full Analysis Set and observed data, and an 
analysis of covariance model with treatment and background therapy as factors and baseline TG as 
a covariate. Baseline TG will  be deﬁned as the average of  and the preceding 
lipid-qualifying visit . For the TG at Week  8, it will be deﬁned as 
the average of measurements at  and  If there are significant 
deviations from the normality assumption of the primary endpoint, the alternative non- parametric 
analysis will be performed using the median of the treatment differences and Hodges -Lehmann 2-
tailed 95% confidence interval, with treatment compar ison using the Wilcoxon rank- sum test .  
Comparison of change from baseline to Week  8 in TG  will be analyzed using the same analysis 
method for the primary endpoint. 
The following sensitivity analysis will be conducted: the percentage change from baseline i n TG at 
each post -baseline study visit be analyzed using a Mixed Effects Model with Repeated Measures 
(model) where the treatment group, time, treatment by time interaction, and the randomization 
stratification factor of background therapy will be included  in the model as fixed effects ; subjects 
will be a random effect; the baseline TG value will be included as a covariate. No imputation for missing data will be made for this sensitivity analysis. The unstructured covariance model will be used. The treatmen t contrast for the analysis at each study visit, including , will 
be estimated by the model.  
9.4.3. Secondary E ndpoint(s)  
The proportion of subject s with TG  <500 mg/dL at Week  8 will be summarized by treatment 
group and analyzed using Cochran Mantel Haenszel (CMH) method stratified by the 
2 stratification factors. T o examine whether the response is consistent over a range of response 
thresholds, responder analysis with other response thresholds will be considered .  
As sensitivity analyses of the r esponder of TG <500 mg/dL at Week  8, comparison between 
BIO89 -100 and placebo groups of proportion of subject s with ≥50% reduction from baseline at 
Week  8 in TG will be analyzed using the CMH test stratified by the 2 stratification factors. To 
examine whether the response is consistent over a range of response thresholds, responder analysis with other response thresholds will be considered. Cumulative distribution function of both 
percentage changes from baseline and changes from baseline for TG at Week  8 by treatment group 
will be summarized descriptively and graphically.  
The analysis methods for the primary endpoint will be used to analyze other similar secondary efficacy endpoints.  
All serum co ncentrations of B IO89-100 will be listed. Pharmacokinetic parameters in the 
Intensive PK group will be determined where possible from the serum concentrations of BIO89 -100. Further details on PK analysis will be provided in the SAP. 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 65 9.4.4. Exploratory E ndpoints  
 
9.4.5. Safety Analyses 
Treatment duration and IP  received will be summarized by treatment group.  
Subject incidence of TEAEs  will be tabulated by Medical Dictionary for Regulatory Activities 
(MedDRA) system organ class, MedDRA preferred term, and treatment group. All TEAEs, all 
treatment- emergent related  AEs , all TESAEs, and all treatment- emergent serious related  AEs  will 
be summarized. Laboratory tests, vital signs, and ECG measures will be summarized by visits and 
by treatment group. 
 
 
9.5. Interim Analyses  
No efficacy interim analysis will be performed.  
9.6. Data Monitoring Committee 
There is no data monitoring committee for this study. 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 66 10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations 
10.1.1. Regulatory and Ethical Considerations 
• This study will be conducted in accordance with the protocol and with the following:  
− Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences International Ethical Guidelines  
− Applicable ICH GCP  Guidelines 
− Applicable laws an d regulations 
• The protocol, protocol amendments, ICF, IB , and other relevant documents (e.g., 
advertisements) must be submitted to an IRB/IEC by the Investigator and reviewed and 
approved by the IRB/IEC before the study is initiated.  
• Any amendments to the protocol will require IRB/IEC approval before implementation 
of changes made to the study design, except for changes necessary to eliminate an 
immediate hazard to study subjects. 
• The Investigator will be responsible for the following: 
− Providing written sum maries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/IEC  
− Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
IRB/IEC procedures 
− Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local 
regulations 
10.1.2. Financial Disclosure  
Investigators and sub- investigators will provide 89bio with sufficient, accurate financial 
inform ation as requested to allow 89bio to submit complete and accurate financial certification or 
disclosure statements to the appropriate regulatory authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after 
completion of the study. 
10.1.3. Informed Consent Process  
• The Investigator or his or her representative will explain the nature of the study to the 
subject or his or her legally authorized representative and answer all questions 
regarding the study. 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 67 • Subject s must be informed that their participation is voluntary. Subject s will be 
required to sign a statement of informed consent that meets the requirements of 
21 CFR 50, local regulations, ICH guidelines, Health Insurance Portability and 
Accountability Act (HI PAA) requirements, where applicable, and the IRB/IEC or 
study center.  
• The medical record must include a statement that written informed consent was obtained before the subject  was enrolled in the study and the date the written consent 
was obtained. The authorized person obtaining the informed consent must also sign the 
ICF. 
• Subject s must be re -consented to the most current version of the ICF(s) during their 
participation in the study.  
• A copy of the ICF(s) must be provided to the subject  or the subject ’s leg ally authorized 
representative.  
10.1.4. Data Protection 
• Subject s will be assi gned a unique identifier by 89bio. Any subject records or datasets 
that are transferred to 89bio will contain the identifier only; subject  names or any 
information which would make the su bject  identifiable will not be transferred.  
• The subject must be informed that his or her personal study -related data will be used by 
89bio in accordance with local data protection law. The level of disclosure must also be 
explained to the subject  who will be required to give consent for their data to be used 
as described in the informed consent . 
• The subject must be informed that his/her medical records may be examined by 
Clinical Quality Assurance auditors or other authorized personnel appointed by 89bio, by appropriate IRB/IEC members, and by inspectors from regulatory authorities.  
10.1.5. Dissemination of Clinical Study Data  
A clinical study report will be developed by 89bio at completion of data analysis. This report will be a clinical and statistical integrated report, according to the ICH E3 guidelines.  
89bio will register the study and post- study results regardless of outcome on a publicly accessible 
website in accordance with the applicable laws and regulations.  
10.1.6. Data Quality Assurance 
• All subject data relating  to the study will be recorded on the eCRFs unless transmitted 
to 89bio or designee electronically ( e.g., laboratory data). The Investigator is 
responsible for verifying that data entries are accurate and correct by electronically signing the eCRF. 
• The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF. 
• The Investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 68 • Monitoring details describing strategy, methods, responsibilities and requirements, 
including handling of non -compliance issues and monitoring techniques (central, 
remote, or on -site monitoring) are provided in the Monitoring Plan.  
• 89bio or designee is responsible for the data management of this study including quality checking of the data. 
• 89bio assumes accountability for actions delegated to other individuals (e.g., CROs ). 
• Study monitors will perform ongoing source data verification to confirm that data entered into the eCRF by authorized site personnel are accurate, complete, and 
verifiable from source documents; that the safety and rights of subjects are being 
protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable 
regulatory requirements . 
• Records and documents, including signed ICFs, pertaining to the conduct of this study 
must be retained by the Investigator per ICH GCP and loc al regulations or institutional 
policies. No records may be destroyed during the retention period without the written 
approval of 89bio. No records may be transferred to another location or party with out 
written notification to 89bio, whether within the retention period or thereafter. 
10.1.7. Source Documents  
• Source documents provide evidence for the existence of the subject and substantiate the integrity of the data collected. Source documents are filed at the Investigator’s site.  
• Data entered in the eCRF that are  transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained. The Investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.  
• Source documents are original documents, data, and records from which the subject ’s 
eCRF data are obtained. These include but are not limited to hospital records, clinical and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs, 
and correspondence. 
10.1.8. Study and Site Start and Closure 
89bio reserves the right to close a study site or terminate the study at any time for any reason. 
Study sites will be closed upon study completion. A study site is considered closed when all 
required documents and study supplies have been collected and a study site closure visit has been 
performed.  
The Investigator may initiate study  site closure at any time, provided there is reasonable cause and 
sufficient notice is given to 89bio in advance of the intended termination.  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 69 Reasons for the early closure of a study site by 89bio or Investigator may include but are not 
limited to:  
• Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC or local health authorities, 89bio’s procedures, or GCP guidelines 
• Inadequate recruitment of subjects by the Investigator 
• Disconti nuation of further IP  development 
• Debarment  
If the study is prematurely terminated or suspended, 89bio shall promptly inform the I nvestigators, 
the IECs/IRBs, the regulatory authorities, and any CRO(s) used in the study of the reason for termination or suspension, as specified by the applicable regulatory requirements. The Investigator shall promptly inform the subject and should assure appropriate subject  therapy and/or follow- up. 
10.1.9. Publication Policy  
• The results of this study may be published or presented at scientific meetings. If this is foreseen, the Investigator agrees to submit all manuscripts or abstracts to 89bio before submission and only present or publish information after approval by 89bio. This 
allows 89bio to protect proprietary information and to provide comments. 
• 89bio will comply with the requirements for publication of study results. In accordance 
with standard editorial and ethical practice, 89bio will generally support publication of 
multicenter studies only in their entirety and not as individual site data. In this case, a 
coordinating Investigator will be designated by mutual agreement. 
• Authorship will be determined by mutual agreement and in line with the International 
Committee of Medical Journal Editors authorship requirements.  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 70 10.2. Appendix 2: Clinical Laboratory Tests 
• The clinical laboratory tests detailed in Table 6  will be performed by a central 
laboratory at timing/frequency detailed in the SoA ( Table  2). Laboratory tests will be 
performed under fasting conditions ( for at least 12 hours ; it is recommended that 
subjects fast no more than 14 hours). Subjects should be instructed to attempt to remain 
consistent in how long they fast prior to blood draws for the duration of the study. 
• Protocol- specific requirements for inclusion or exclusion of subject s are detailed in 
Section  5 of the protocol.  
• Additional tests may be performed at any time during the study as determined 
necessary by the Investigator or required by local regulations. 
• Investigator s must document their review of each laboratory safety report. 
Table  6: Protocol- Requi red Laboratory Assessments  
Hematology   
WBC with differential ( Total 
Neutrophils, Lymphocytes, Monocytes, 
Eosinophils, Basophils – absolute and 
%) RBC count  
RBC Indices : 
MCV, MCH, MCHC, RDW, Reticulocyte  count  
Hemoglobin Hematocrit  
Platelet count Coagulation panel , including PT, INR, aPTT  
Lipid Assessment   
 non- HDL -C* 
ApoB * RLP-C* 
  
HDL -C* TG* 
 VLDL -C*  
LDL -C* VLDL -TG* 
  
Clinical Chemistries   
ALP  Fasting plasma glucose  
ALT  GGT  
AST  Lactate dehydrogenase 
Albumin  Magnesium  
Bicarbonate  Phosphorus  
BUN  Potassium  
Calcium  Sodium  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 71 Creatinine,  eGFR  Total bilirubin, Indirect/direct bilirubin  
CK Total protein  
Chloride  Uric acid  
Urinalysis   
Basic urinalysis (dipstick, including 
macroscopic appearance, bilirubin, 
blood, color, glucose, ketones, leukocyte 
esterase, nitrite, pH, protein, specific gravity, urobilinogen);  Full urinalysis (dipstick plus microscopic evaluation) to be performed only at the s creening and End of Study visits). A 
reflex microscopic urinalysis should be performed if the results of the urinalysis are  abnormal or at the discretion of 
the PI or delegate.  
Other Study -Specific Laboratory 
Assessments   
BIO89-100 (to be evaluated by bioanalytical laboratory)  
Thyroid function assessment (TSH, 
free T4, and free T3)   
 
 
Serum hCG pregnancy test 
Urine hCG pregnancy test# 
FSH level  
Urine drug screen including amphetamines, barbiturates, cocaine metabolites, opiates, benzodiazepines, cannabinoids and phencyclidine  
 
Serology – HIV antibody, hepatitis B 
surface antigen (HBsAg, and HCV 
antibody).  To determine current 
infection status, if H BsAg positive HBV 
DNA will be measured , if HCV antibody 
positive, HCV RNA will be measured , 
and if HIV antibody positive will be differentiated by HIV 1 or 2 and HIV RNA will be measured.  
24-hour  urine for cortisol  and creatinine 
 
 
 
Insulin  
hsCRP 
 
 
Serum adiponectin , total 
 
 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 72 * Post -baseline  lipid panels to be blinded  
# Tests can be performed locally with kits provided by the central laboratory  
Abbreviations:  ALP = alkaline phosphatase; ALT = alanine aminotransferase; ; 
ApoB = apolipoprotein  B100 ; ; aPTT = activated parti al thromboplastin time ; 
AST  = aspartate aminotransferase; ; BUN = blood urea nitrogen; CK = creatine 
kinase ; ; DNA  = deoxyribonucleic acid ; eGFR = estimated 
glomerular filtration rate  using CKD -EPI ( Chronic Kidney Disease  Epidemiology Collaboration ) equation; 
; FSH = follicle -stimulating hormone ; GGT  = gamma -glutamyl transferase; HBsAg = Hepatitis 
B surface antigen ; ; HBV = Hepatitis B virus ; hCG = human chorionic gonadotropin; HCV 
= Hepatitis C Virus ; HDL -C = high- density  lipoprotein -cholesterol; HIV = human immunodeficiency virus ;  
; INR = international normalized ratio ; LDL -C = lipoprotein- cholesterol ;  
; MCH =  mean corpuscular hemoglobin; MCHC = mean corpuscular hemoglobin concentration; PT = 
prothrombin time ; PINP = n-terminal propeptide of type  I procollagen; MCV = Mean Corpuscular Volume ; Non-
HDL -C = non-high-density  lipoprotein -cholesterol ; RBC = red blood cell; RDW  = Red Cell Distribution Width ; RLP -
C = remnant lipoprotein -cholesterol ; RNA  = ribonucleic acid ; T3 = triiodothyronine; T4  = thyroxine ;  
; TG = triglyceride s; TSH = thyroid- stimulating  hormone ; VLDL -C = very low -density  lipoprotein 
cholesterol ; VLDL -TG = very low -density  lipoprotein triglycerides ; WBC  = white blood cell . 
10.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting 
10.3.1. Definition of AE  
AE Definition 
• An AE is any untoward medical occurrence in a clinical study subject , temporally associated with 
the use of IP , whether or not considered related to the IP. 
• NOTE: An AE can, therefore, be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IP. 
 
Events Meetin g the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments ( e.g., ECG, radiological scans, vital signs measurements), including those that worsen 
from baseline are considered clini cally significant in the medical and scientific judgment of the 
Investigator (i.e., not related to progression of underlying disease).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase in 
frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after IP administration even though it may have been present 
before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the cl inical sequelae of a suspected overdose of either IP or a concomitant 
medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming intent. Such overdoses should be reported regardless of 
sequelae.  
 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 73 Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments which 
are associated with the underlying disease, unless judged by the Investigator to be more severe than expected for the subject’s condition.  
• The disease/disord er being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the subject ’s condition.  
• Medical or surgical procedure ( e.g., endoscopy, appendectomy): the condition that leads to the  
procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or detected at 
the start of t he study that do not worsen.  
10.3.2. Definition of Suspected and Unsuspected Adverse Reaction  
Suspected adverse reactions are defined as:  
• Any AE for which there is a reasonable possibility that the IP caused the AE. For the purposes of 
89bio  regulatory safety reporting, “reasonable possibility” means there is evidence to suggest a 
causal relationship between the IP and the AE. A suspected adverse reaction implies a lesser degree 
of certainty about caus ality than adverse reaction, which means any AE caused by an IP 
Unexpected  AEs are defined as:  
• AE which is not listed in the IB of the IP  or is not listed at the specificity or severity that has been 
observed  
10.3.3. Definition of Events to Monitor  
89bio -defined Events to Monitor for BIO89 -100:  
Events to Monitor include hypersensitivity reactions occurring after the first administration of study 
agent(s) in subject s participating in this clinical study. These events must be reported by the Investigator 
to 89bio within 24 hours and are to be considered serious (for regulatory reporting purposes) only if they 
meet the definition of an SAE. The event s are to be reported on an SAE form  
10.3.4. Definition of SAE  
If an event is not an AE per definition in Section  10.3.1, then it cannot be an SAE even if serious 
conditions are met (e.g., hospitalization for signs/symptoms of the disease under study, death due 
to progression of disease). 
An SAE is defined as any untoward medical occurrence that, at any dose:  
1. Results in death 
2. Is life-threatening  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 74 An SAE is defined as any untoward medical occurrence that, at any dose:  
The term ‘life-threatening ’ in the definition of ‘serious ’ refers to an event in which the subject  was at 
risk of death at the time of the event. It does not refer to an event, which hypothetically might have 
caused death, if it were more severe.  
3. Requires inpatient hospitalization or prolongation of existing hospitalization 
In general, hospitalization signifies that the subject has been detained (usually involving at least an 
overnight stay) at the hospital  or emergency ward for observation and/or treatment that would not have 
been appropriate in the physician’s office or outpatient setting. Complications that occur during hospitalization are  AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, 
the event is serious. When in doubt as to whether “hospitalization” occurred or was necessary, the AE should be considered serious.  
Hospitalization for elective treatment of a pre-existing condition that did not worsen from baseline is not considered an AE.  
4. Results in persistent disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct normal life functions.  
• This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma ( e.g., 
sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.  
5. Is a congenital anomaly/birth defect  
6. Other situati ons: 
• Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject  or may require 
medical or surgical intervention to prevent  1 of the other outcomes listed in the above definition. 
These events should usually be considered serious.  
• Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse.  
10.3.5. Recording and Follow -Up of AE and/or SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the Investigator to review all documentation (e.g., hospital progress notes, laboratory reports, and diagnostics reports) related to the event.  
• The Investigator will then record all relevant AE/SAE information in the eCRF/paper case report form (CRF) as appropriate . 
• It is not acceptable for the Investigator to send photocopies of the subject’s medical records to the Medical Monitor in lieu of completion of the AE/SAE eCRF page  and paper CRF as ap propriate . 
• There may be instances when copies of medical records for certain cases are requested by the Medical Monitor. In this case, all subject  identifiers, with the exception of the subject  number, will 
be redacted on the copies of the medical records before submission to the Medical Monitor.  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 75 AE and SAE Recording  
• The Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or 
other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) 
will be documented as the AE/SAE.  
Assessment of Intensity  
The severity of each AE will be assessed at onset by a nurse and/or physician. When recording the outcome of the AE the maximum severity of the AE experienced will also be recorded. The severity of the AE will be  graded according to the CTCAE v5.0:  
Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. 
Grade 2: Moderate; minimal, local, or non -invasive intervention indicated; limiting age -appropriate 
instrumental Activities of Daily Living (ADL)*. Grade 3: Severe or medically significant but not immediately life -threatening; hospitalization or 
prolongation of hospitalization indicated; disabling; limiting self -care ADL**.  
Grade 4: Life -threatening consequences; urgent intervention indicated.  
Grade 5: Death related to AE.  
ADL:  
*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing 
money, etc.  
**Self -care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and 
not bedridden.  
 
Assessment of Causality  
The Investigator is obligated to assess the relationship between IP and each occurrence of each 
AE/SAE. 
• A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.  
• The Investigator will use clinical judgment to determine the relationship.  
• Alternative  causes, such as underlying disease(s), concomitant therapy, and other risk factors, as 
well as the temporal relationship of the event to IP administration will be considered and 
investigated.  
• The Investigator will also consult the IB and/or Product Information, for marketed products, in 
his/her assessment.  
• For each AE/SAE, the Investigator must  document in the medical notes that he/she has reviewed 
the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the Investigator has minimal 
information to include in the initial report to the Medical Monitor. However, it is very 
important that the Investigator always make s an assessment of causality for every event 
before the initial transmission of the SAE data to the Medical Monitor.  
• The Investigator may change his/her opinion of causality in light of follow -up information and 
send an SAE follow -up report with the updated causality assessment.  
• The causality assessment is 1 of the criteria used when determining  regulatory reporting 
requirements.  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 76 Assessment of Causality  
Causality Categories:  
• UNRELATED – This relationship suggests that there is no association between the IP and the 
reported event.  
• UNLIKELY RELATED – The relationship suggests that the event is more likely due to other 
causes than IP , however the relationship to the IP cannot be ruled out.  
• POSSIBLY RELATED – This relationship is based on evidence suggesting a causal relationship 
between the IP and the AE, i .e., there is a reasonable possibility that the drug caused the even t. 
The event follows a reasonable temporal sequence from the time of drug administration or 
follows a known response pattern to the IP but could also have been produced by other factors.  
• PROBABLY RELATED – This relationship suggests that a reasonable temporal sequence of the 
event with drug administration exists and, based upon the known pharmacological action of the drug, known or previously reported adverse reactions to the drug or class of drugs, or judgment based on the Investigator’s clinical experience, the association of the event with the IP seems 
likely.  
• DEFINITELY RELATED – This relationship suggests that a definite causal relationship exists 
between drug administration and the AE, and other conditions (concurrent illness, 
progression/expression of  disease state, or concurrent medication reaction) do not appear to 
explain the event.  
 
Follow -up of  AEs and SAEs  
• The Investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by the Medical Monitor to elucidate the nature and/or causality of the AE or SAE as fully as possible. This may include additional 
laboratory tests or investigations, histopathological examinations, or consultation with other health 
care professionals.  
• If a subject  dies during participation in the study or during a recognized follow -up period, the 
Investigator will provide the Medical Monitor with a copy of any post -mortem findings including 
histopathology.  
• New or updated information will be recorded in the originally completed eCRF  and paper CRF as 
appropriate . 
• The Investigator will submit any updated SAE data to 89bio within 24 hours of receipt of the information.  
10.3.6. Reporting of SAEs  
Reporting of SAEs will be done using a paper CRF . 
SAE Reporting to the Medical Monitor via Paper CRF  
• Facsimile or email transmission of the SAE paper CRF is the preferred method to transmit this information to the Medical Monitor.  
• In rare circumstances and in the absence of facsimile or email equipment , notification by telephone 
is acceptable with a copy of the SAE data collection tool sent by overnight mail or courier service.  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 77 SAE Reporting to the Medical Monitor via Paper CRF  
• Initial notification via telephone does not replace the need for the Investigator to complete and sign 
the SAE CRF pages within the designated reporting time frames.  
• Contacts for SAE reporting can be found in the relevant manual.  
10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information  
Definitions:  
WOCBP  
A woman is considered fertile following menarche and until becoming post menopausal  unless 
permanently sterile (see below).  
If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of IP , additional evaluation should be considered. 
Wome n in the Following Categories A re Not C onsidered WOCBP  
1. Premenarchal  
2. Premenopausal female with  1 of the following:  
• Documented hysterectomy  
• Documented bilateral salpingectomy   
• Documented bilateral oophorectomy  
• For individuals with permanent infertility due to an alternate medical cause other than 
the above, (e.g., Mullerian agenesis, androgen insensitivity), Investigator discretion 
should be applied to determining study entry. 
• Note: Documentation can come from the site personnel’s review of the subject’s medical records or medical examination. An ultrasound to document absence of a uterus is considered acceptable documentation of non -childbearing potential. 
3. Postmenopausal female  
• A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.  
− A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, 
confirmation with more than  1 FSH measurement is required.  
• Females on HRT and whose menopausal status is in doubt will be required to use 1 of 
the non-estrogen hormonal highly-effective contraception methods if they wish to 
continue their HRT during the study. Otherwise, they must discontinue HRT to allow 
confirmation of postmenopausal status before study enrollment. 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 78 Contraception Guidance:  
Contraceptive use by men or women should be consistent with local regulations regarding the 
methods of contraception for those participating in clinical studies.  
Subjects should use highly-effective, double contraception ( with both male/ female partners) 
during the study and for 30 days or 5 half- lives (whichever is longer) of IP . 
Double contraception is defined as a condom with 1 of any of the following forms of birth control:  
• Birth control pills (The Pill)  
• Depot or injectable birth control  
• IUD 
• Birth Control Patch (e.g., Ortho Evra) 
• NuvaRing® 
• Documented evidence of tubal ligation  prior to screening visit for women or history of 
vasectomy for men  
Subject s must not donate sperm or oocytes during the study and for 30 days or 5 half- lives 
(whichever is longer) after last dose of IP . 
Rhythm methods are not considered as highly- effectiv e methods of birth control. Subject 
abstinence for the duration of the study and 30 days or 5 half- lives (whichever is longer) after last 
dose of IP  is acceptable if it is the subject’s regular practice.  
Collection of Pregnancy Information 
Male Subjects wi th Partners who Become Pregnant  
• The Investigator will attempt to collect pregnancy information on any male subject’s 
female partner who becomes pregnant while the male subject is in this study. This 
applies only to male subject s who receive IP . 
• After obtaining the necessary signed informed consent from the pregnant female partner directly, the Investigator will record pregnancy information on the appropriate form and submit it to 89bio within 24 hours of learning of the partner’s pregnancy. The 
female partn er will also be followed to determine the outcome of the pregnancy. 
Information on the status of the mother and child will be forwarded to 89bio. Generally, the follow-up will be no longer than 6 to 8 weeks following the estimated 
delivery date. Any termination of the pregnancy will be reported regardless of fetal 
status (presence or absence of anomalies) or indication for the procedure.  
Female S ubjects w ho B ecome P regnant  
• The Investigator will collect pregnancy information on any female subject who 
becomes pregnant while participating in this study. Information will be recorded on the 
appropriate form and submitted to 89bio within 24 hours of learning of a subject’ s 
pregnancy. This applies only to female subject s who receive IP . 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 79 • The subject will be followed  to determine the outcome of the pregnancy. The 
Investigator will collect follow -up information on the subject  and the neonate, and the 
information will be forwarded to 89bio. Generally, follow- up will not be required for 
longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of 
pregnancy will be reported, regardless of fetal status (presence or absence of 
anomalies) or indication for the procedure. 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy will be reported as an AE or SAE. 
A spontaneous abortion is always considered to be an SAE and will be reported as such. Any post-study pregnancy related SAE considered reasonably related to the IP by 
the Investigator will be reported to 89bio as described in Section  8.3.4. While the 
Investigator is not obligated to actively seek this information in former study subjects, he or she may learn of an SAE through spontaneous reporting. 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 80 10.5. Appendix 5: Abbreviations  
Abbreviation Term  Description  
~ Approximately  
ABV  Alcohol By Volume  
  
  
ADL  Activities of Daily Living  
AE Adverse Event  
ALP Alkaline Phosphatase  
ALT Alanine Aminotransferase (SGPT)  
AP Acute Pancreatitis  
Apo Apolipoprotein  
  
ApoB  Apolipoprotein B100 
  
  
aPTT  Activated Partial Thromboplastin Time  
AST  Aspartate Aminotransferase (SGOT)  
AUC  Area Under t he Curve  
AUC 0-tau Area Under t he Curve during the Dosing Interval  
  
BMI  Body Mass Index  
BP Blood Pressure  
BUN  Blood Urea Nitrogen  
CBC Complete Blood Count  
CK Creatine Kinase 
CKD -EPI Chronic Kidney Disease  Epidemiology Collaboration  
Cmax Maximum Concentration  
CMH  Cochran Mantel Haenszel  
COVID -19 Coronavirus Disease 2019  
CRF  Case Report Form  
CRO  Contract Research Organization  
CTCAE  Common Terminology Criteria for Adverse Events  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 81 Abbreviation Term  Description  
  
CVD  Cardiovascular Disease  
CYP3A Cytochrome P450 3A  
DHA  Docosahexaenoic acid  
DILI  Drug -induced Liver Injury  
DNA  Deoxyribonucleic Acid  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form  
eGFR  Estimated Glomerular Filtration Rate  
EOS End of Study 
EOT End of Treatment  
EPA Eicosapentaenoic acid  
FDA Food and Drug Administration 
  
FGF21  Fibroblast Growth Factor 21  
FGFR  Fibroblast Growth Factor Receptor  
FSH Follicle -Stimulating Hormone  
GCP  Good Clinical Practice  
GGT  Gamma -Glutamyl Transferase  
GI Gastrointestinal 
  
HBV  Hepatitis B Virus  
HBsAg  Hepatitis B Surface Antigen  
HCG  Human Chorionic Gonadotropin 
HCV  Hepatitis C Virus  
HDL -C High -Density  Lipoprotein Cholesterol  
HHP  Home health provider  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
HRT  Hormone replacement therapy  
hsCRP  High -Sensitivity C-r eactive Protein  
IB Investigator Brochure  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 82 Abbreviation Term  Description  
ICF Informed Consent Form  
IEC Independent Ethics Committee  
ICH International Council for Harmoni sation  
  
INR International Normalized Ratio  
IP Investigational Product  
IRB Institutional Review Board  
ISR Injection Site Reaction  
IUD Intrauterine Device  
IVRS  Interactive Voice  Response System  
IWRS  Interactive Web Response System  
LDL Low-Density Lipoprotein  
LDL-C Low-Density Lipoprotein Cholesterol  
  
MAD Multiple Ascending Dose  
MCV  Mean Corpuscular Volume  
MCH  Mean Corpuscular Hemoglobin 
MCHC  Mean Corpuscular Hemoglobin Concentration  
MedDRA  Medical Dictionary for Regulatory Activities  
MRI  Magnetic Resonance Imaging  
MRI -PDFF Magnetic Resonance Imaging – Whole Liver Proton Density Fat Fraction  
NAb  Neutralizing Antibody  
NAb - Neutralizing Antibody Negative  
NAFLD Non-Alcoholic Fatty Liver Disease  
NASH  Non-Alcoholic Steatohepatitis  
NOAEL  No Observed Adverse Effect Level  
PCSK9  Proprotein Convertase Subtilisin/Kexin Type 9  
PD Pharmacodynamic  
PDFF Proton Density Fat Fraction  
PEG Polyethylene Glycol  
PI Principal Investigator  
  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 83 Abbreviation Term  Description  
PK Pharmacokinetic  
PT Prothrombin Time  
QW Every Week  
Q2W  Every 2 weeks  
QTcF  Fridericia’s -corrected QT interval  
RBC Red Blood Cell  
RDW  Red Cell Distribution Width  
RLP-C Remnant Lipoprotein Cholesterol  
RNA  Ribonucleic Acid  
RR Respiratory Rate  
SAD Single Ascending Dose  
SAE  Serious Adverse Events  
SAP Statistical Analysis Plan  
SC Subcutaneous  
SD Standard Deviation  
SHTG  Severe Hypertriglyceridemia  
SoA Schedule of Assessments  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
t½ Half-life 
T1DM Type 1 Diabetes Mellitus  
T2DM Type 2 Diabetes Mellitus  
T3 Triiodothyronine  
T4 Thyroxine  
  
TEAE Treatment -Emergent Adverse Event  
TESAE Treatment -Emergent Serious Adverse Events  
TG Triglycerides  
tmax Time to Maximum Concentration  
TSH Thyroid -Stimulating  Hormone  
ULN Upper Limit of Normal  
V Visit  
VLDL -C Very Low -Density Lipoprotein Cholesterol  
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A

Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 84 Abbreviation Term  Description  
VLDL -TG Very Low -Density Lipoprotein Triglycerides  
WBC White Blood Cell  
WOCBP  Women of Childbearing Potential 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 85 11. REFERENCES  
Berglund L, Brunzell JD, Goldberg AC, et al . Evaluation and treatment of hypertriglyceridemia: 
an Endocrine Society clinical practice guideline. J C lin Endocrinol Metab. 2012;97(9):2969-89.  
Berglund L, Brunzell JD, Goldberg AC, et al. Treatment options for hypertriglyceridemia: from 
risk reduction to pancreatitis. Best Practice & Research Clinical Endocrinology & Metabolism. 
2014;28(3):423-37. 
Blom DJ. E levated triglycerides: A matter of the heart and pancreas. South African Medical 
Journal. 2018;108(4):258-61. 
Brisson D, Methot J, Tremblay K, et al. Comparison of the efficacy of fibrates on 
hypertriglyceridemic phenotypes with different genetic and clini cal characteristics. 
Pharmacogenetics and genomics. 2010;20(12):742-7. 
Caussy C, Reeder SB, Sirlin CB, and Loomba R. Noninvasive, Quantitative Assessment of Liver 
Fat by MRI- PDFF as an Endpoint in NASH Trials. Hepatology. 2018;68(2):763-772. 
Charles ED, Ne uschwander ‐Tetri BA, Pablo Frias J, et al. Pegbelfermin (BMS ‐986036), 
PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study. Obesity. 2019;27(1):41-9. 
Chowdhury IN. FDA Medical Review for Vascepa (Application number 202057Orig1s000). 
Retrieved 27 Nov 2019: 
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202057Orig1s000MedR.pdf. Center for Drug Evaluation and Research. 2012. 
Chowdhury IN. FDA Medical Review for Epanova (Application number 205060Orig1s000). 
Retrieved 27 Nov 2019: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205060Orig1s000MedR.pdf. Center 
for Drug Evaluation and Research. 2014. 
de Pretis N, Amodio A, Frulloni L. Hypertriglyceridemic pancreatitis: epidemiology, 
pathophysiology and clinical management. United European Gastroenterology Journal. 
2018;6(5):649-55. 
FDA. HIGHLIGHTS OF PRESCRIBING INFORMATION - Lopid® ( Gemfibrozil) tablets, for 
oral use, Revised 2017. Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/label /2018/018422s058lbl.pdf accessed 1 2th 
December 2019. 
FDA. HIGHLIGHTS OF PRESCRIBING INFORMATION - TRICOR® ( fenofibrate ) Capsules, 
for oral use Initial U.S. Approval: 1993 [updated 11/2018]. Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021203s008lbl.pdf accessed 1 2th 
December 2019. 
Gaich G, Chien JY, Fu H, et al.  The effects of LY2405319, an FGF21 analog, in obese human 
subjects with type 2 diabetes. Cell Metab. 2013;18(3): 333-340. 
Galman C, Lundasen T, Kharitonenkov A, et al.  The circulating metabolic regulator FGF21 is 
induced by prolonged fasting and PPARα activation in man. Cell Metab. 2008;8(2):169-74. 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 86 Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., et al 
(2019). “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA 
Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the 
American College of Cardiology/American Heart Association Task Force on Clinica l Practice 
Guidelines.” J Am Coll Cardiol 73(24): 3168-3209. 
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E, Jones, P. H., et al. (2015). 
“National Lipid Association Recommendations for Patient- Centered Management of 
Dyslipidemia: Pa rt 1—Full Report.” Journal of Clinical Lipidology 9(2): 129-169. 
Jellinger PS, Handelsman Y, Rosenblit PD, et al . American Association of Clinical 
Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocrine Practice. 2017;23(s2):1 -87.  
Kiss L, Fur G, Matrai P, et al. The effect of serum triglyceride concentration on the outcome of acute pancreatitis: systematic review and meta -analysis. Scientific reports. 2018;8(1):14096. 
Li M, Reynolds CM, Segovia SA, et al . Developmental Programming of Nonalcoholic Fatty Liver 
Disease: The Effect of Early Life Nutrition on Susceptibility and Disease Severity in Later Life.  
BioMed research international 2015:1-12. 
Mu J, Pinkstaff J, Li Z, et al. FGF21 analogs of sustained action enabled by orthogonal 
biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes. 
2012;61(2):505-512. 
Nordestgaard BG. Triglyceride- rich lipoproteins and atherosclerotic cardiovascular disease: new 
insights from epidemiology, genetics, and biology. C irculation research. 2016;118(4):547-63.  
Ogawa Y, Kurosu H, Yamamoto M, et al. BetaKlotho is required for metabolic activity of 
fibroblast growth factor 21.  Proc Natl Acad Sci U S A . 2007;104(18):7432-7437. 
Sanyal A, Charles ED, Neuschw ander- Tetri BA, et al . Pegbelfermin (BMS -986036), a PEGylated 
fibroblast growth factor 21 analogue, in patients with non- alcoholic steatohepatitis: a randomised, 
double-blind, placebo-controlled, phase 2a trial. Lancet . 2018;392(10165):2705-2717. 
Sanyal A, Charles ED, Neuschwander -Tetri BA, et al. Pegbelfermin (BMS -986036), a PEGylated 
fibroblast growth factor 21 analogue, in patients with non- alcoholic steatohepatitis: a randomised, 
double-blind, placebo-controlled, phase 2a trial. Lancet. 2019;392(10165):2705-2717. 
Scherer J,  Singh V, Pitchumoni CS, et al . Issues in hypertriglyceridemic pancreatitis -an update. 
Journal of cli nical gastroenterology. 2014;48(3):195-203. 
Talukdar S, Zhou Y, Li D, et al. A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body 
Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects. Cell 
metabolism.  2016;23(3):427-440. 
Woolsey SJ, Beaton MD, Mansell SE, Leon -Ponte M, Yu J, Pin CL, et al. A fibroblast growth 
factor 21 – pregnane X receptor pathway downregulates hepatic cytochrome P450 3A4 in non-alcoholic fatty liver disease. Mol Pharmacol. 2016 Oct;90(4):437-46. 
Yoon SB, Lee IS, Choi MH, et al. Impact of fatty liver on acute pancreatitis severity . 
Gastroenterol Res Pract. 2017:4532320. 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A
Protocol BIO89- 100-221 
V 3.0, 03 May 2021  
89bio  Confidential  Page 87 Zhang J, Zhao Y, Xu C, et al. Association between serum free fatty acid levels and non- alcoholic 
fatty liver disease: a cross- sectional study. Sci Rep . 2014;4. 
DocuSign Envelope ID: C43A0E91-6D49-4590-9B1D-0319A2D4038A